documents incorporated reference parts ii iii portions registrants annual report shareholders fiscal year annual reportparts iii portions registrants proxy statement annual meeting shareholders filed within days close registrants fiscal year proxy statementitem pag e part business general segments business geographic areas raw materials patents trademarks seasonality competition research development environment regulation available information risk factors b unresolved staff comments properties legal proceedings submission matters vote security holders executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis financial condition results operation quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accounting fees services part iv exhibits financial statement schedules schedule ii valuation qualifying accounts signatures report independent registered public accounting firm financial statement schedule exhibit index exr summary compensation arrangements named executive officers directors ex statement computation ratio earnings fixed charges ex pages company 's annual report shareholders ex subsidiaries ex consent pricewaterhousecoopers llp exa certification exb certification exa certification exb certification ex cautionary statementtable contents part item business general johnson johnson subsidiaries approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world johnson johnsons primary focus products related human health wellbeing johnson johnson incorporated state new jersey companys structure based principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located segments business johnson johnsons operating companies organized three business segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments operating results captions managements discussion analysis results operations financial condition pages note segments business geographic areas notes consolidated financial statements annual report filed exhibit report consumer consumer segment includes broad range products used baby care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products major brands include aveeno skin care products bandaid brand adhesive bandages carefree pantiliners clean clear teen skin care products johnsons baby adult lines products listerine oral care products motrin ib ibuprofen products neutrogena skin hair care products roc skin care products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co rembrandt brand oral care products splenda calorie sweetener stayfree sanitary protection products sudafed cold flu allergy products broad family tylenol acetaminophen products vendme skin care product lines products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical pharmaceutical segment includes products following therapeutic areas antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology products distributed directly retailers wholesalers health care professionals prescription use general public key products pharmaceutical segment include risperdal oral risperidone medication treats symptoms schizophrenia bipolar mania irritability associated autistic behavior indicated patients risperdal consta risperidone longacting injectable invegatm paliperdone extended release tablets treatment schizophrenia remicade infliximab biologic approved treatment crohns disease ankylosing spondylitis psoriasis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis procrit epoetin alfa sold outside us eprex biotechnologyderived product stimulates red blood cell production topamax topiramate approved adjunctive monotherapy use epilepsy well prophylactic treatment migranes levaquin levofloxacin floxin ofloxacin antiinfective field aciphexpariet proton pump inhibitor comarketed eisai inc duragesicfentanyl transdermal fentanyl transdermal system sold outside us durogesic treatment chronic pain offers novel delivery system concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder ortho evratable contents norelgestrominethinyl estradiol transdermal system first contraceptive patch approved us food drug administration fda medical devices diagnostics medical devices diagnostics segment includes broad range products distributed wholesalers hospitals retailers used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring insulin delivery products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses distribution health care professional markets done directly surgical supply dealers geographic areas international business johnson johnson conducted subsidiaries located countries outside united states selling products virtually countries throughout world products made sold international business include many described segments business consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside united states subject higher risks comparable us activities investment commercial climate influenced restrictive economic policies political uncertainties raw materials raw materials essential johnson johnsons operating companies businesses generally readily available multiple sources patents trademarks johnson johnson operating companies made practice obtaining patent protection products processes possible licensed number patents relating products manufacturing processes aggregate believed material importance johnson johnson operation businesses sales companys two largest products risperdal remicade accounted approximately johnson johnsons total revenues respectively fiscal accordingly patents related products believed material johnson johnson whole duragesicfentanyl transdermal fentanyl transdermal system lost basic patent protection subject generic competition united states certain international markets basic patents covering eprex epoetin alfa expired increased biosimilar competition international markets expected duragesicfentanyl transdermal sales declined billion compared due impact generic competition combined sales duragesicfentanyl transdermal eprex accounted approximately johnson johnsons worldwide sales material patents expired expire related risperdal expired united states december topamax scheduled expire united states september company received pediatric extension risperdal oral fda grants market exclusivity united states june company target file pediatric extension topamax obtained fda would grant market exclusivity united states march table contents johnson johnsons operating companies made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines johnson johnsons operating companies compete companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important johnson johnsons success areas businesses also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance products johnson johnsons consumer businesses involves significant expenditures advertising promotion research development research activities represent significant part johnson johnsons subsidiaries businesses major research facilities located united states also australia belgium brazil canada china france germany india japan netherlands singapore united kingdom costs worldwide companysponsored research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumers patients excluding inprocess research development charges amounted million million million fiscal years respectively costs charged directly income year incurred environment johnson johnsons operating companies subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnsons compliance requirements past year expected material effect upon capital expenditures cash flows earnings competitive position regulation johnson johnsons businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation united states drug device diagnostics cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside united states costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent force market table contents place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care united states implementation medicare prescription drug improvement modernization act deficit reduction act may cause uncertainty reimbursement levels certain product segments regulatory agencies whose purview johnson johnsons operating companies operate administrative powers may subject companies actions product withdrawals recalls seizure products civil criminal sanctions cases johnson johnsons operating companies may deem advisable initiate product recalls addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties available information companys main corporate web site address wwwjnjcom copies johnson johnsons quarterly reports form q annual report current reports form k filed furnished us securities exchange commission sec amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys sec filings also available companys web site wwwinvestorjnjcomgovernancecfm soon reasonably practicable electronically filed furnished sec sec filings also available secs web site wwwsecgov addition written charters audit committee compensation benefits committee nominating corporate governance committee board directors companys principles corporate governance policy business conduct employees code business conduct ethics members board directors executive officers available wwwinvestorjnjcomgovernancecfm web site address provided without charge shareholder submitting written request provided item risk factors applicable item b unresolved staff comments applicable item properties johnson johnson subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments johnson johnsons business approximately follows square feet segment thousands consumer pharmaceutical medical devices diagnostics worldwide total within united states eight facilities used consumer segment pharmaceutical segment medical devices diagnostics segment johnson johnsons manufacturing operations outside united states often conducted facilities serve one business segment table contents locations manufacturing facilities major geographic areas world follows square feet number geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed johnson johnson subsidiaries maintain numerous office warehouse facilities throughout world research facilities also discussed item business research development johnson johnson subsidiaries generally seek manufacturing facilities although principally locations abroad leased office warehouse facilities often leased johnson johnsons properties maintained good operating condition repair well utilized information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements annual report filed exhibit report segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements annual report filed exhibit report item legal proceedings information set forth note legal proceedings notes consolidated financial statements pages annual report incorporated herein reference filed exhibit report company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company item submission matters vote security holders applicable executive officers registrant listed executive officers johnson johnson february unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal table contents information regard directors company including following executive officers directors incorporated herein reference material captioned election directors proxy statement name age position dominic j caruso member executive committee vice president finance chief financial officera donald casey jr member executive committee worldwide chairman comprehensive care groupb russell c deyo member executive committee vice president general counsel c kaye fostercheek member executive committee vice president human resourcesd colleen goggins member executive committee worldwide chairman consumer groupe sherilyn mccoy member executive committee worldwide chairman surgical care groupf christine poon vice chairman board directors member executive committee worldwide chairman pharmaceuticals group joseph c scodari member executive committeeg nicholas j valeriani member executive committee vice president strategy growthh william c weldon chairman board directors chairman executive committee chief executive officer mr j caruso joined company company acquired centocor inc time acquisition senior vice president finance centocor mr caruso named vice president finance ortho mcneil pharmaceutical inc vice president group finance companys medical devices diagnostics group mr caruso named vice president companys group finance organization mr caruso became member executive committee vice president finance chief financial officer january b mr casey jr joined company held various positions becoming president johnson johnson merck consumer pharmaceuticals co named president personal products company division johnson johnson consumer companies inc mr casey became group president johnson johnson vision care inc named company group chairman vision care november named company group chairman lifescan franchise january became member executive committee worldwide chairman comprehensive care group c mr r c deyo joined company became associate general counsel became member executive committee vice president administration vice president general counsel ms k fostercheek joined company vice president human resources johnson johnson consumer products companies march named vice president human resources consumer personal care group named member human resources leadership team consumer personal care group operating committee ms fostercheek became member executive committee vice president human resources company prior joining company ms fostercheek served various human resources management positions pfizer inc years recently supporting pharmaceutical businesses japan asia africa middle east latin america e ms c goggins joined company held various positions becoming president personal products company named president johnson johnson consumer companies inc company group chairman north america johnson johnson consumer products ms goggins became member executive committee worldwide chairman consumer personal care group known consumer group table contents f ms mccoy joined company associate scientist research development personal products company named vice president research development personal products worldwide division mcneilppc inc vice president marketing skin care franchise ms mccoy became global president baby wound care franchise named company group chairman worldwide franchise chairman ethicon inc january became member executive committee worldwide chairman surgical care group g mr j c scodari joined company president centocor inc company acquired centocor time acquisition president chief operating officer centocor member centocors board directors since december named company group chairman north american pharmaceutical business became member pharmaceuticals group operating committee mr scodari named company group chairman biopharmaceutical businesses mr scodari became member executive committee worldwide chairman pharmaceuticals group mr scodari plans retire company march h mr n j valeriani joined company held various positions becoming president ethicon endosurgery inc named company group chairman ethicon endosurgery additional responsibility johnson johnson medical products medical devices diagnostics business canada became worldwide franchise chairman depuy franchise mr valeriani became member executive committee vice president human resources assumed additional responsibilities worldwide chairman diagnostics mr valeriani appointed worldwide chairman cardiovascular devices diagnostics relinquished human resources responsibilities became worldwide chairman medical devices diagnostics group january mr valeriani became vice president strategy growth part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference material captions managements discussion analysis results operations financial condition liquidity capital resources share repurchase dividends information common stock market prices note common stock stock option plans stock compensation agreements notes consolidated financial statements pages shareholder return performance graphs annual report filed exhibit report item security ownership certain beneficial owners management related stockholder matters equity compensation plan information report issuer purchases equity securities july company announced board directors approved stock repurchase program authorizing company buy back billion companys common stock share repurchases take place open market time time based market conditions repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends fund share repurchase program combination available cash debt company expect triplea credit rating effected share repurchase program addition common stock purchases open market made part systematic plan related companys compensation programs table contents following table provides information respect common stock purchases company fiscal fourth quarter total number shares remaining purchased maximum number part shares total number avg price publicly announced may yet purchased shares paid per plans plans period purchased share programs programs october october october november november december total fiscal fourth quarter company repurchased aggregate shares companys common stock pursuant repurchase program publicly announced july aggregate shares openmarket transactions outside program december based closing price companys common stock new york stock exchange december per share item selected financial data information called item incorporated herein reference material caption summary operations statistical data annual report filed exhibit report item managements discussion analysis financial condition results operation information called item incorporated herein reference narrative tabular graphic material caption managements discussion analysis results operations financial condition pages annual report filed exhibit report item quantitative qualitative disclosures market risk information called item incorporated herein reference material caption managements discussion analysis results operations financial condition liquidity capital resources financing market risk note summary significant accounting policies financial instruments notes consolidated financial statements pages annual report filed exhibit report item financial statements supplementary data information called item incorporated herein reference audited consolidated financial statements notes thereto material caption report independent registered public accounting firm pages annual report filed exhibit report table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure william c weldon chairman chief executive officer dominic j caruso chief financial officer reviewed participated evaluation based evaluation messrs weldon caruso concluded end period covered report companys disclosure controls procedures effective managements annual report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation financial statements accordance generally accepted accounting principles internal control financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal control financial reporting based companys processes assessment described management concluded december companys internal control financial reporting effective effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears report independent registered public accounting firm annual report incorporated herein reference filed exhibit report changes internal control financial reporting fiscal quarter ended december changes companys internal control financial reporting identified connection evaluation referred item materially affected reasonably likely materially affect companys internal control financial reporting item b information applicable table contents part iii item directors executive officers corporate governance information called item incorporated herein reference material captions election directors stock ownership section compliance section b beneficial ownership reporting compliance discussion audit committee caption corporate governance board committees proxy statement material caption executive officers registrant part report companys policy business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act policy business conduct available companys web site wwwinvestorjnjcomgovernancepoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller posted companys web site wwwinvestorjnjcomgovernancecfm within five business days retained web site least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys web site wwwinvestorjnjcomgovernancepoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code waiver code granted member board directors executive officer posted companys web site wwwinvestorjnjcomgovernance within five business days retained web site least one year item executive compensation information called item incorporated herein reference material captions compensation discussion analysis executive director compensation compensation committee report proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent registrant specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters additional information called item incorporated herein reference material captions stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements pages annual report filed exhibit report equity compensation plan information following table provides certain information december concerning shares companys common stock may issued existing equity compensation plans table contents number securities weighted average number securities issued upon exercise exercise price remaining available outstanding options outstanding warrants future issuance plan category warrants rights options rights equity compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders stock option plan stock option plan stock compensation plan longterm incentive plan included category shares common stock company issuable various equity compensation plans assumed company upon acquisition following companies alza corporation scios inc innovasive devices inc inverness medical technology inc centocor inc shares listed issuable category issued plans approved shareholders companies prior acquisition assumption plans company time acquisitions options acquire equity acquired company replaced options acquire common stock company stock options equity awards type made plans since assumption plans company stock options equity awards type made plans future shares included column issued plans approved shareholders applicable acquired company shares issuable scios nonofficer stock option plan shares issuable alza nonstatutory plan shares issuable warrants inverness medical plan also included category shares common stock company issuable upon exercise outstanding stock options companys stock option plan nonemployee directors column excludes shares reflected column number securities issued upon exercise outstanding options warrants rights item certain relationships related transactions director independence information called item incorporated herein reference material captions transactions related persons corporate governance director independence proxy statement item principal accounting fees services information called item incorporated herein reference material caption ratification appointment independent registered public accounting firm proxy statement table contents part iv item exhibits financial statement schedules following documents filed part report financial statements following audited consolidated financial statements notes thereto material caption report independent registered public accounting firm pages annual report incorporated herein reference filed exhibit report consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm financial statement schedules schedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report table contents johnson johnson subsidiaries schedule ii valuation qualifying accounts fiscal years ended december december january dollars millions balance balance beginning end period accruals payments period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million million million december december january respectively includes million related previously estimated performancebased rebate allowances managed care contracts table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date w c weldon chairman board directors february w c weldon chief executive officer director principal executive officer c poon vice chairman board directors director february c poon j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february coleman j g cullen director february j g cullen e johns director february e johns table contents signature title date g langbo director february g langbo l lindquist director february l lindquist l f mullin director february l f mullin w perez director february w perez c prince director february c prince reinemund director february reinemund satcher director february satcher table contents report independent registered public accounting firm financial statement schedule shareholders board directors johnson johnson audits consolidated financial statements effectiveness internal control financial reporting referred report dated february appearing annual report shareholders johnson johnson report consolidated financial statements incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york february table contents exhibit index reg sk exhibit table description item exhibit ai restated certificate incorporation dated april incorporated herein reference exhibit registrants annual report year ended december aii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit registrants annual report year ended january aiii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit aiii registrants annual report year ended december aiv certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrants form q quarterly report quarter ended july av certificate amendment restated certificate incorporation company effective april incorporated herein reference exhibit registrants form q quarterly report quarter ended april b bylaws company amended effective january incorporated herein reference exhibit registrants form k current report filed january upon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrants annual report year ended december b stock option plan amended incorporated herein reference exhibit b registrants annual report year ended december c stock option plan amended incorporated herein reference exhibit b registrants annual report year ended january stock compensation plan incorporated herein reference exhibit e registrants annual report year ended december e longterm incentive plan incorporated herein reference exhibit registrants registration statement filed commission may file f form stock option certificate restricted shares nonemployee directors certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended july g form restricted stock unit certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended october h executive bonus plan incorporated herein reference exhibit registrants form registration statement filed commission november file executive incentive plan amended incorporated herein reference exhibit f registrants annual report year ended december j domestic deferred compensation certificate extra compensation plan amended incorporated herein reference exhibit g registrants annual report year ended december k deferred fee plan nonemployee directors amended incorporated herein reference exhibit h registrants annual report year ended january table contents reg sk exhibit table description item exhibit l executive income deferral plan amended incorporated herein reference exhibit registrants annual report year ended december excess savings plan incorporated herein reference exhibit j registrants annual report year ended december n supplemental retirement plan incorporated herein reference exhibit h registrants annual report year ended january executive life insurance plan incorporated herein reference exhibit registrants annual report year ended january p stock option gain deferral plan incorporated herein reference exhibit registrants annual report year ended january q estate preservation plan incorporated herein reference exhibit n registrants annual report year ended january r summary compensation arrangements named executive officers directors filed document statement computation ratio earnings fixed charges filed document pages companys annual report shareholders fiscal year portions annual report incorporated reference report deemed filed filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document b certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document management contract compensatory plan copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company exr yexvwrhtm exr summary compensation arrangements named executive officers directors exhibit r summary compensation arrangements named executive officers directors compensation arrangements named executive officers following description compensation arrangements approved compensation benefits committee board directors johnson johnson compensation committee february companys chief executive officer chief financial officer three highly compensated executive officers named executive officers annual base salary compensation committee approved following base salaries effective february january case mr caruso named executive officers william c weldon chairmanceo dominic j caruso vice president finance cfo christine poon vice chairman russell c deyo vice president general counsel colleen goggins worldwide chairman consumer group performance bonus compensation committee approved following bonus performance payments performance paid form cash company common stock determined compensation committee mr weldon mr caruso ms poon mr deyo ms goggins stock option restricted share unit grantsthe compensation committee approved following stock option restricted share unit rsu grants companys longterm incentive plan lti plan stock options granted exercise price fair market value calculated average high low prices companys common stock new york stock exchange february options become exercisable february expire february rsus vest february upon holder still employed company date receive one share companys common stock rsu mr weldon stock options rsus mr caruso stock options rsus ms poon stock options rsus mr deyo stock options rsus ms goggins stock options rsusnonequity incentive plan awards compensation committee approved following nonequity incentive plan awards recognition performance companys certificate extra compensation cec program awards paid retirement termination employment end fiscal year cec value per unit cec unit value vary time based performance company awards cec units granted every executive officer every year mr weldon cec units mr caruso cec units equity compensation nonemployee directors nonemployee director receives nonretainer equity compensation first quarter year lti plan form shares restricted common stock fair market value grant date accordingly nonemployee director granted shares restricted common stock lti plan february service board restricted shares become freely transferable february ex yexvhtm ex statement computation ratio earnings fixed charges exhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions fiscal ear ended december december january january december determination earnings earnings provision taxes income fixed charges total earnings defined fixed charges rents interest expense capitalization interest total fixed charges ratio earnings fixed charges ratio earnings fixed charges computed dividing sum earnings provisio n ta xes income f ix ed charg es fixed charges f ixe charg es represent ter est expe ns e int ere st ca pit alized amortization debt discount appropriate interest factor operating leases ex yexvhtm ex pages company 's annual report shareholders exhibit table contents managements discussion analysis organization business segments results operations analysis sales business segments analysis consolidated earnings provision taxes income liquidity capital resources information cautionary factors may affect future results audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements equity consolidated statements cash flows notes consolidated financial statements managements report internal control financial reporting report independent registered public accounting firm summary operations statistical data shareholder return performance graphs johnson johnson annual report managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment includes broad range products used baby care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring insulin delivery products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses companys structure based upon principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located product lines company competes companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important companys success areas business also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance companys consumer products involves significant expenditures advertising promotion managements objectives primary objective company achieve superior levels capital efficient profitable growth accomplish companys management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services new products introduced within past five years accounted approximately sales billion sales invested research development increase billion increase reflects managements commitment importance ongoing development new differentiated products services sustain longterm growth operating companies located countries company views principle decentralized management asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges company committed developing global business leaders drive growth objectives businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareholders unifying management team companys dedicated employees achieving objectives credo credo provides common set values serves constant reminder companys responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry results operations analysis consolidated sales worldwide sales increased billion compared increases sales increases consisted following sales increase due volume price currency total sales us companies billion billion billion represents increase sales international companies billion billion billion represents increase johnson johnson annual reportbar chart fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively bar chart international geographic regions experienced sales growth consisting europe western hemisphere excluding us asiapacific africa regions sales increases include impact currency fluctuations us dollar foreign currencies positive impacts europe western hemisphere excluding us asiapacific africa region acquisition pfizer incs consumer healthcare business net related divestitures increased total sales growth operational growth company customer represented total revenues bar chart analysis sales business segments consumer segment consumer segment sales billion increase change due operational growth remaining due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations acquisition pfizer incs consumer healthcare business net related divestitures increased total sales growth operational growth total consumer segment overthecounter otc pharmaceuticals nutritionals franchise sales billion increase attributable new products acquisitions well strong sales growth achieved analgesics splenda products positive impact otc pharmaceuticals nutritionals total sales growth due newly acquired brands pfizer inc fiscal year company announced voluntary withdrawal certain infant cough cold products market used directed medicines generally recognized safe effective however assessment available data use pediatric cough cold medicines identified rare instances misuse leading overdose particularly infants two years age well products along childrens cough cold products generally subject recent us food drug administration fda nonprescription drug advisory committee hearing recommended fda certain changes marketing major consumer franchise sales change dollars millions vs vs otc pharmaceuticals nutritionals skin care baby care womens health oral care total prior year amounts reclassified conform current presentation managements discussion analysis results operations financial condition sale products actions expected significant impact sales otc pharmaceuticals nutritionals franchise skin care franchise sales billion representing increase increase primarily due sales growth suncare clean clear aveeno neutrogena product lines well new products related acquisitions positive impact skin care total sales growth due newly acquired brands pfizer inc fiscal year baby care franchise sales grew billion strong growth led success cleanser haircare lotion cream powder product lines additional contributor growth new products related acquisitions positive impact baby care total sales growth due newly acquired brands pfizer inc divestitures related acquisition fiscal year womens health franchise sales grew billion growth primarily due newly acquired brands pfizer inc positive impact womens health total sales growth due newly acquired brands pfizer inc fiscal year oral care franchise sales grew billion strong sales growth attributable new products acquisitions newly launched products listerine mouthwashes dissolvable whitening strips positive impact oral care total sales growth due newly acquired brands pfizer inc divestitures related acquisition consumer segment sales billion increase operational growth accounting total growth due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations pharmaceutical segment pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency fluctuations us pharmaceutical segment sales billion increase international pharmaceutical segment sales billion increase included operational growth related positive impact currency fluctuations antipsychotics franchise achieved sales billion increase prior year antipsychotics franchise includes risperdal oral risperidone medication treats symptoms schizophrenia bipolar mania irritability associated autistic behavior indicated patients risperdal consta risperidone long acting injectable invega paliperdone extendedrelease tablets treatment schizophrenia sales growth positively impacted continued global success risperdal consta patent risperdal compound expired us major markets outside us march fda granted pediatric exclusivity risperdal extends marketing exclusivity us risperdal oral end june us sales risperdal oral billion loss market exclusivity risperdal oral likely result significant reduction sales us remicade infliximab biologic approved treatment crohns disease ankylosing spondylitis psoriasis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis achieved sales billion growth prior year growth driven increased demand due expanded indications overall market growth remicade received approval european commission pediatric crohns disease indications remicade competing market experiencing increased competition due new entrants expansion indications existing competitors procrit epoetin alfa eprex epoetin alfa combined sales billion decline compared prior year decline primarily due declining markets erythropoiesis stimulating agents esas earlier year centers medicare medicaid issued national coverage determination significantly limits reimbursement esas oncology us epoetin alfa products us subject label change may negatively impact future sales label epoetin alfa products also review jurisdictions outside us major pharmaceutical product revenues change dollars millions vs vs antipsychotics remicade infliximab procriteprex epoetin alfa topamax topiramate levaquin floxin levofloxacinofloxacin aciphexpariet rabeprazole sodium duragesic fentanyl transdermal fentanyl transdermal system concerta methylphenidate hci hormonal contraceptives total prior year amounts reclassified conform current presentation johnson johnson annual reporttopamax topiramate approved adjunctive monotherapy use epilepsy well prophylactic treatment migraines achieved billion sales increase prior year major contributor growth continued success migraine category patent topamax topiramate us expire september company target file pediatric extension fda obtained would grant market exclusivity us march us sales topamax billion expiration product patent loss market exclusivity likely result significant reduction sales levaquin levofloxacin floxin ofloxacin achieved combined sales billion representing growth prior year primarily due favorable market growth partially offset increased competitive pressure march fda granted pediatric exclusivity us levaquin extend marketing exclusivity six months june aciphexpariet rabeprazole sodium proton pump inhibitor comarketed eisai co ltd achieved sales billion increase compared prior year growth us due overall market growth growth outside us due market growth partially offset increased competition certain regions duragesicfentanyl transdermal fentanyl transdermal system sales declined billion reduction decline result impact generic competition us major international markets generic competition us began january concerta methylphenidate hci product treatment attention deficit hyperactivity disorder achieved sales billion representing increase although original concerta patent expired fda approved generic version substitutable concerta two parties filed abbreviated new drug applications andas generic versions concerta pending may approved time hormonal contraceptive franchise sales declined billion reduction ortho evra norelgestrominethinyl estradiol first contraceptive patch approved fda experienced significant decline sales result labeling changes negative media coverage concerning product safety sales decline also result continued generic competition oral contraceptives pharmaceutical sales billion representing growth prior year biggest contributor increase velcade product treatment multiple myeloma fiscal fourth quarter company recorded special pretax noncash charge million writedown intangible asset related natrecor nesiritide product treatment patients acutely decompensated heart failure dyspnea rest minimal activity charge results revised estimates future cash flows product primarily due recent decline natrecor sales trends remaining unamortized intangible value associated natrecor million end company believes natrecor important clinical option treatment acutely decompensated heart failure product continue marketed scios inc subsidiary company company launched invega paliperidone extendedrelease tablets us europe additionally company launched antibacterial doribax doripenem injection us antiretroviral prezista darunavir europe company submitted five new molecular entities approval paliperidone palmitate schizophrenia us ustekinumab cnto psoriasis us europe dapoxetine premature ejaculation several countries europe antibacterial ceftobiprole us europe antihiv medication tmc us europe tmc approved us fda january marketed intelence etravirine response challenges facing pharmaceutical segment company announced restructuring initiative see note additional information regarding restructuring pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales billion increase international pharmaceutical segment sales billion increase included operational growth related positive impact currency medical devices diagnostics segment medical devices diagnostics segment achieved sales billion representing increase prior major medical devices diagnostics franchise sales change dollars millions vs vs depuy ethicon endosurgery ethicon cordis lifescan vision care orthoclinical diagnostics total managements discussion analysis results operations financial condition year operational growth due positive impact currency fluctuations us sales billion increase international sales billion increase operations positive currency impact depuy franchise achieved billion sales increase prior year growth primarily due depuys orthopaedic joint reconstruction products including hip knee product lines strong performance also achieved miteks sports medicine products ethicon endosurgery franchise achieved sales billion increase major contributor growth continues endocutter sales include products used performing bariatric procedures treatment obesity important focus area franchise strong results achieved continued success harmonic scalpel ultrasonic cutting coagulating surgical device also strong growth advanced sterilization products line ethicon franchise sales grew achieving billion sales result solid growth hemostasis womens health biosurgicals mesh product lines also continued growth suture sales sales cordis franchise billion decline decline reflects lower sales cypher sirolimuseluting coronary stent due increased competition outside us well global contraction drug eluting stent market following reports potential risk late stent thrombosis associated use drugeluting stents results partially offset strong performance biosense webster neurovascular businesses response challenges facing cordis franchise company announced restructuring initiative see note additional information regarding restructuring june fda notified cordis items outlined warning letters received april july regarding good manufacturing practice regulations good clinical practice regulations resolved lifescan franchise achieved billion sales increase reflecting continued success ultra product lines additional contributor growth animas business due launch insulin pump year vision care franchise achieved sales billion growth rate prior year growth led continued success brands acuvue oasys acuvue advance astigmatism acuvue advance day acuvue moist day acuvue define day acuvue astigmatism orthoclinical diagnostics franchise achieved billion sales increase due continued global growth immunohematology product line well growth immunodiagnostic product line launch chagas screening assay us medical devices diagnostics segment achieved sales billion representing increase prior year operational growth negative impact currency us sales billion increase international sales billion increase operations negative currency impact analysis consolidated earnings provision taxes income consolidated earnings provision taxes income decreased billion billion compared billion earned lower earnings primarily due restructuring charges writedown natrecor intangible asset increase billion percent sales consolidated earnings provision taxes income versus sections follow highlight significant components changes consolidated earnings provision taxes income cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows sales cost products sold percent point increasedecrease prior year selling marketing administrative expenses percent point increasedecrease prior year increase percent sales cost products sold primarily due impact newly acquired consumer brands increase percent sales selling marketing administrative expenses primarily due impact newly acquired consumer brands partially offset cost containment efforts increase percent sales cost products sold due unfavorable product mix higher manufacturing costs pharmaceutical consumer segments decrease percent sales selling marketing administrative expenses result leveraging selling expenses reduction advertising promotional spending decrease percent sales cost products sold due lower manufacturing costs primarily related cypher sirolimuseluting coronary stent well ongoing cost containment activity across organization partially offset negative impact pharmaceutical product mix also decrease percent sales selling marketing administrative expenses due cost containment initiatives pharmaceutical segment partially offset increases investment spending medical devices diagnostics segment research development research development activities represent significant part companys business expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumers patients worldwide costs research johnson johnson annual reportactivities excluding inprocess research development charges follows dollars millions research development expense percent increase prior year percent sales research development expense percent sales pharmaceutical segment research development expense percent sales medical devices diagnostics segment research development expense percent sales consumer segment research development activities pharmaceutical segment increased billion compound annual growth rate approximately fiveyear period since increased investment research development segments demonstrates companys focus knowledgebased products reflects significant number projects latestage development restructuring company announced initiatives expected generate pretax annual cost savings billion effort improve overall cost structure company recorded million related pretax charges action taken offset anticipated negative impacts associated generic competition pharmaceutical segment challenges drugeluting stent market companys pharmaceuticals segment reduce cost base consolidating certain operations continuing invest recently launched products latestage pipeline new products cordis franchise moving integrated business model address market changes underway drugeluting stents better serve broad spectrum patients cardiovascular needs reducing cost base program allow company accelerate steps standardize streamline certain aspects enterprisewide functions human resources finance information technology support growth across business also leveraging scale effectively areas procurement benefit operating companies see note details inprocess research development company recorded charge inprocess research development iprd million tax related acquisition conor medsystems inc iprd charge included operating profit medical devices diagnostics segment company recorded iprd charges million tax related acquisitions consumer healthcare business pfizer inc vascular control systems inc ensure medical inc colbar lifescience ltd hand innovations llc future medical systems sa consumer healthcare business pfizer inc accounted million tax iprd charges included operating profit consumer segment iprd charges following acquisitions included operating profit medical devices diagnostics segment vascular control systems inc privately held company focused developing medical devices treat fibroids control bleeding obstetric gynecologic applications accounted million tax iprd charges ensure medical inc privately held company develops devices postcatheterization closure femoral artery accounted million tax iprd charges colbar lifescience ltd privately held company specializing reconstructive medicine tissue engineering accounted million tax iprd charges hand innovations llc privately held manufacturer fracture fixation products upper extremities accounted million tax iprd charges future medical systems sa privately held company primarily develops manufactures markets arthroscopic fluid management systems accounted million tax iprd charges company recorded iprd charges million tax related acquisitions transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc international commercial rights certain patents knowhow field sedation analgesia scott lab inc transform pharmaceuticals inc company specializing discovery superior formulations novel crystalline forms drug molecules accounted million tax iprd charges included operating profit pharmaceutical segment closure medical corporation company expertise intellectual property biosurgicals market accounted million tax iprd charges included operating profit medical devices diagnostics segment peninsula pharmaceuticals inc biopharmaceutical company focused developing commercializing antibiotics treat lifethreatening infections accounted million tax iprd charges included operating profit pharmaceutical segment million tax iprd charge related scott lab inc referred included operating profit medical devices diagnostics segment income expense net income expense net includes gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gains losses disposal property plant equipment currency gains losses minority interests litigation settlements liabilities royalty income change income expense net increase expense million income expense net included charge million tax related natrecor intangible asset writedown gain million associated guidant acquisition agreement termination fee less associated expenses included addition also included expenses associated recording additional product liability reserves integration costs associated acquisition consumer healthcare business pfizer inc income expense net included royalty income partially offset several expense items none individually significant managements discussion analysis results operations financial condition operating profit segment operating profits segment business follows percent segment sales dollars millions consumer pharmaceutical med devices diag total less expensesincome allocated segments earnings provision taxes income see note details amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense bar graph consumer segment consumer segment operating profit increased percent sales operating profit increased iprd expenses million well expenses associated consumer healthcare business pfizer inc integration recorded consumer segment operating profit decreased percent sales declined prior year resulting million iprd expenses well expenses associated consumer healthcare business pfizer inc integration recorded pharmaceutical segment pharmaceutical segment operating profit decreased percent sales operating profit decreased resulting million restructuring charges million natrecor intangible asset writedown pharmaceutical segment operating profit increased percent sales increased prior year increase result million iprd recorded partially offset increases research development spending lower gross margins medical devices diagnostics segment operating profit medical devices diagnostics segment decreased percent sales operating profit decreased resulting million iprd expenses million restructuring charges included gain associated guidant acquisition agreement termination fee less associated expenses million medical devices diagnostics segment operating profit increased percent sales increased prior year primary driver improved operating profit guidant acquisition agreement termination fee less associated expenses million recorded partially offset higher iprd charges million versus million addition advertising promotional expense leveraging offset part increases research development spending interest income expense interest income decreased million due lower average cash balance decline average cash balance due primarily acquisition consumer healthcare business pfizer inc december cash balance including marketable securities billion end averaged billion compared billion average cash balance interest expense increased million due higher average debt balance net debt balance end billion compared billion end higher debt balance due debt associated acquisition consumer healthcare business pfizer inc common stock repurchase program interest income increased million due primarily higher rates interest well higher average cash balance despite billion common stock repurchase program increase acquisition activity compared prior year cash balance including current marketable securities billion end averaged billion compared billion average cash balance interest expense increased slightly compared due higher average debt balance billion billion partially offset decrease interest rates interest income increased million due primarily higher rates interest well higher average cash balance cash balance including current marketable securities billion end averaged billion compared billion average cash balance provision taxes income worldwide effective income tax rate tax rate benefited onetime gain million related international business restructuring certain countries well increases taxable income lower tax jurisdictions relative taxable income higher tax jurisdictions lower international tax rates certain countries tax rate increased compared primarily due gain million recorded partially offset benefit related reversal tax allowance million associated international business effective tax rate benefited previously mentioned million due reversal tax liability previously recorded fiscal fourth quarter related technical correction american jobs creation act liquidity capital resources cash flows cash flow operations billion increase billion billion increase cash flow operations primarily attributable noncash expenses associated natrecor intangible asset writedown johnson johnson annual reportand increased depreciation amortization net cash used investing activities billion versus billion included acquisition consumer healthcare business pfizer inc detailed discussion mergers acquisitions see note also billion net increase purchases investments primarily marketable securities capital expenditures billion billion billion respectively net cash used financing activities decreased billion primarily due billion decrease repurchase common stock billion increase proceeds exercise stock options partially offset billion decrease proceeds short longterm debt also billion increase dividends shareholders cash current marketable securities billion end compared billion end primarily due cash flow operations cash generated operations amounted billion billion cash generated operations billion major factors contributing increase net income increase billion net noncash impact iprd charges billion increase accounts payable accrued liabilities partially offset billion increase deferred taxes billion increase current noncurrent assets bar graph financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency products costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote total credit available company approximates billion billion expires september billion expires september total borrowings end billion billion respectively increase borrowings result financing general corporate purposes common stock repurchase program net debt cash current marketable securities net debt billion compared net debt billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend increase period ended december material cash commitments johnson johnson continues one industrial companies triple credit rating summary borrowings found note managements discussion analysis results operations financial condition contractual obligations commitments company contractual obligations primarily lease debt obligations unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities december see notes audited consolidated financial statements details unfunded operating debt retirement dollars millions leases obligations plans total total amounts include interest expense tax matters see note share repurchase dividends july company announced board directors approved stock repurchase program authorizing company buy back billion companys common stock repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends fund share repurchase program combination available cash debt company repurchased aggregate million shares johnson johnson common stock current repurchase program cost billion addition company annual program repurchase shares use employee stock incentive plans company increased dividend th consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows first quarter second quarter third quarter fourth quarter total january board directors declared regular cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock options revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs derived estimating sales volumes incentive period recorded products sold promotional arrangements containing customer acceptance criteria evaluated determine appropriate amounts deferred addition company enters collaboration arrangements contain multiple revenue generating activities revenue arrangements recognized activity performed delivered based relative fair value upfront fees received part arrangements performance obligations exist recognized revenue earlier receipt payment collection assured performance obligations exist company defer upfront fees recognize earned obligation period johnson johnson annual reportreasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business years ended december december consumer segment balance balance beginning payments end dollars millions period accruals period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset pharmaceutical segment balance balance beginning payments end dollars millions period accruals period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset medical devices diagnostics segment balance balance beginning payments end dollars millions period accruals period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers income taxes income taxes recorded based amounts refundable payable current year include results difference gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future management believes changes estimates would material effect companys results operations cash flows financial position company adopted fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return interpretation also provides guidance derecognition classification matters see note information regarding income taxes december december cumulative amounts undistributed international earnings approximately billion billion respectively company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation managements discussion analysis results operations financial condition legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability cases arise normal course business accruals based managements judgment probability losses opinions legal counsel applicable actuarially determined estimates additionally company records insurance receivable amounts thirdparty insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note detail rates effect rate change would companys results operations stock options fiscal first quarter company adopted statement financial accounting standards sfas r share based payment company applied modified retrospective transition method implement sfas r previously reported financial statements restated accordance provisions sfas r see note information regarding stock options new accounting pronouncements june financial accounting standards board fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return interpretation also provides guidance derecognition classification matters fin effective fiscal year company adopted first quarter september fasb issued sfas fair value measurements statement defines fair value establishes framework measuring fair value generally accepted accounting principles expands disclosures fair value measurements statement effective fiscal first quarter except nonfinancial assets liabilities recognized disclosed fair value recurring basis effective date fiscal years beginning november company believes adoption sfas material effect results operations cash flows financial position february fasb issued sfas fair value option financial assets financial liabilities permits entity measure certain financial assets financial liabilities fair value sfas effective fiscal year company adopt accordingly company assessing impact adoption sfas currently believe adoption material impact results operations cash flows financial position december fasb issued sfas r business combinations noncontrolling interests consolidated financial statements statements aim improve simplify converge internationally accounting business combinations reporting noncontrolling interests consolidated financial statements statements effective fiscal years beginning december sfas r significant impact manner company accounts future acquisitions beginning fiscal year significant changes include capitalization iprd expensing acquisition related restructuring actions transaction related costs recognition contingent purchase price consideration fair value acquisition date company believes adoption sfas r sfas material effect results operations cash flows financial position eitf issue accounting collaborative arrangements related development commercialization intellectual property issue effective financial statements issued fiscal years beginning december issue addresses income statement classification payments made parties collaborative arrangement adoption eitf expected significant impact companys results operations cash flows financial position eitf issue accounting nonrefundable advance payments goods services received use future research development activities issue effective financial statements issued fiscal years beginning december issue requires nonrefundable advance payments research development capitalized recognized expense related goods delivered services performed adoption eitf expected significant impact companys results operations cash flows financial position economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period united states weighted average compound annual growth rate companys net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases company faces various worldwide health care changes may result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement johnson johnson annual reportthe company also operates environment become increasingly hostile intellectual property rights generic drug firms filed andas seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged anda filings generic firms introduce generic versions product issue resulting potential substantial market share revenue losses product information see discussion litigation filers abbreviated new drug applications note legal proceedings company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued companys balance sheet selfinsurance program thirdparty product liability insurance company also involved number patent trademark lawsuits well investigations incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however companys opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued companys balance sheet expected material adverse effect companys financial position although resolution reporting period one matters could significant impact companys results operations cash flows period see note information regarding legal proceedings common stock market prices companys common stock listed new york stock exchange symbol jnj composite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements company undertake update forwardlooking statements result new information future events developments risks uncertainties include general industry conditions competition economic conditions interest rate currency exchange rate fluctuations technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents us foreign health care reforms governmental laws regulations trends toward health care cost containment increased scrutiny health care industry government agencies product efficacy safety concerns resulting product recalls regulatory action companys report year ended december includes exhibit discussion additional factors could cause actual results differ expectations company notes factors permitted private securities litigation reform act managements discussion analysis results operations financial condition consolidated balance sheets johnson johnson subsidiaries december december dollars millions except share per share data note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes goodwill net notes deferred taxes income note assets note total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson annual reportconsolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note restructuring note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes see notes consolidated financial statements consolidated financial statements consolidated statements equity johnson johnson subsidiaries note receivable accumulated employee treasury comprehensive retained stock ownership comprehensive common stock stock dollars millions note total income earnings plan esop income issued amount amount balance january net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensive income balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealized gains securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensive income balance december see notes consolidated financial statements johnson johnson annual reportconsolidated statements cash flows johnson johnson subsidiaries dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles stock based compensation purchased inprocess research development intangible asset writedown natrecor deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions increase accounts receivable decreaseincrease inventories increasedecrease accounts payable accrued liabilities increasedecrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed net cash paid acquisitions see notes consolidated financial statements consolidated financial statements notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment manufactures markets broad range products used baby care skin care oral care wound care womens health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring insulin delivery products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses new accounting pronouncements june financial accounting standards board fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return interpretation also provides guidance derecognition classification matters fin effective fiscal year company adopted first quarter september fasb issued statement financial accounting standards sfas fair value measurements statement defines fair value establishes framework measuring fair value generally accepted accounting principles expands disclosures fair value measurements statement effective fiscal first quarter except nonfinancial assets liabilities recognized disclosed fair value recurring basis effective date fiscal years beginning november company believes adoption sfas material effect results operations cash flows financial position february fasb issued sfas fair value option financial assets financial liabilities permits entity measure certain financial assets financial liabilities fair value sfas effective fiscal year company adopt accordingly company assessing impact adoption sfas currently believe adoption material impact results operations cash flows financial position december fasb issued sfas r business combinations noncontrolling interests consolidated financial statements statements aim improve simplify converge internationally accounting business combinations reporting noncontrolling interests consolidated financial statements statements effective fiscal years beginning december sfas r significant impact manner company accounts future acquisitions beginning fiscal year significant changes include capitalization iprd expensing acquisition related restructuring actions transaction related costs recognition contingent purchase price consideration fair value acquisition date company believes adoption sfas r sfas material effect results operations cash flows financial position eitf issue accounting collaborative arrangements related development commercialization intellectual property issue effective financial statements issued fiscal years beginning december issue addresses income statement classification payments made parties collaborative arrangement adoption eitf expected significant impact companys results operations cash flows financial position eitf issue accounting nonrefundable advance payments goods services received use future research development activities issue effective financial statements issued fiscal years beginning december issue requires nonrefundable advance payments research development capitalized recognized expense related goods delivered services performed adoption eitf expected significant impact companys results operations cash flows financial position cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value management determines appropriate classification investment debt equity securities time purchase reevaluates determi johnson johnson annual reportnation balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows necessary charges impairments longlived assets recorded amount present value future cash flows less carrying value assets revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products includes sales customers promotional arrangements containing customer acceptance criteria evaluated determine appropriate amounts deferred addition company enters collaboration arrangements contain multiple revenue generating activities revenue arrangements recognized activity performed delivered based relative fair value upfront fees received part arrangements performance obligations exist recognized revenue earlier receipt payment collection assured performance obligations exist company defer upfront fees recognize earned obligation period shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets goodwill sfas requires goodwill nonamortizable intangible assets assessed annually impairment company completed annual impairment test fiscal fourth quarter impairment determined future impairment tests performed annually fiscal fourth quarter sooner triggering event occurs intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets financial instruments company follows provisions sfas accounting derivative instruments hedging activities amended sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product third party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive notes consolidated financial statements income underlying transaction affects earnings reclassified earnings account hedged transaction fair value derivative instrument ie forward foreign exchange contract currency swap aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings insignificant company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available result cost availability factors effective november company ceased purchasing thirdparty product liability insurance based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion income taxes company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation december december cumulative amount undistributed international earnings approximately billion billion respectively deferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies intangible asset liability valuations instance determining annual pension postemployment benefit costs company estimates rate return plan assets cost future health care benefits actual results may may differ estimates annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks inventories end inventories comprised dollars millions raw materials supplies goods process finished goods property plant equipment end property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectivelyupon retirement disposal property plant equipment costs related amounts accumulated depreciation johnson johnson annual reportor amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december dollars millions total commitments capital leases significant employee related obligations end employee related obligations dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation less current benefits payable employee related obligations prepaid employee related obligations million million respectively included assets consolidated balance sheet borrowings components longterm debt follows effective effective dollars millions rate rate zero coupon convertible subordinated debentures due debentures due debentures due notes due debentures due notes due debentures due notes due notes due gbp notes due b euro debentures due includes industrial revenue bonds less current portion weighted average effective rate translation rate december company access substantial sources funds numerous banks worldwide total credit available company approximates billion billion expire september billion expire september interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material company filed shelf registration securities exchange commission became effective november enables company issue billion debt securities warrants purchase debt securities company issued bonds august total billion november total billion general corporate purposes common stock repurchase program december company billion remaining shelf registration july alza corporation subsidiary company completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity december outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures holders entitled convert debentures approximately million shares johnson johnson common stock price per share approximately million shares issued december due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july issue price plus accreted original issue discount december december fair value based quoted market value debentures million million respectively shortterm borrowings current portion longterm debt amounted approximately billion end billion raised commercial paper program remainder represents principally local borrowing international subsidiaries aggregate maturities longterm obligations commencing dollars millions certain business relationships member companys board directors former chief executive officer major bank bank provided services company payments made significant either company bank company plans engage bank provide notes consolidated financial statements services including investment banking services company company anticipate payments services significant either bank company intangible assets goodwill end gross net amounts intangible assets goodwill dollars millions trademarks nonamortizable gross less accumulated amortization trademarks nonamortizable net patents trademarks gross less accumulated amortization patents trademarks net intangibles gross less accumulated amortization intangibles net subtotal intangible assets gross less accumulated amortization subtotal intangible assets net goodwill gross less accumulated amortization goodwill net total intangible assets goodwill gross less accumulated amortization total intangible assets goodwill net goodwill december december allocated segment business follows med dev dollars millions consumer pharm diag total goodwill january acquisitions translationother goodwill december acquisitions translationother goodwill december weighted average amortization periods patents trademarks intangible assets years years respectively amortization expense amortizable intangible assets fiscal years ended december december january million million million tax respectively certain patents intangible assets written fair value fiscal years resulting charge included amortization expense reduction total patent trademarks compared primarily due writedown million tax related natrecor intangible asset remaining unamortized intangible value associated natrecor million end charge results revised estimates future cash flows product due primarily recent decline natrecor sales trends natrecor continue marketed scios inc subsidiary company estimated amortization expense five succeeding years approximates million tax per year substantially amortization expense included cost products sold income taxes provision taxes income consists dollars millions currently payable us taxes international taxes deferred us taxes international taxes comparison income tax expense us statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax ratesus statutory rate puerto rico ireland operations research orphan drug tax credits us state local international subsidiaries excluding ireland technical corrections act impact tax liability us manufacturing deduction process research development iprd us tax international income effective tax rate company subsidiaries manufacturing ireland incentive tax rate addition company subsidiaries operating puerto rico various tax incentive grants also us possessions tax credit expired applies certain operations puerto rico decrease tax rate mainly attributed increases taxable income lower tax jurisdictions relative taxable income higher jurisdictions lower international tax rates certain countries international tax rate also benefited business restructuring certain international subsidiaries resulting onetime benefit million reduced effective tax rate johnson johnson annual reportthe increase tax rate mainly due reversal tax liability million reported tax provision resulted technical correction american jobs creation act partially offset benefit reported reversal tax allowances million associated international business temporary differences carry forwards follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangibles miscellaneous us total deferred income taxes difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet company adopted fin accounting uncertainty income taxes effective january resulted recognition additional million previously unrecognized tax benefits corresponding adjustment retained earnings company billion gross unrecognized tax benefits billion net unrecognized tax benefits january including previous adjustment mentioned company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities interest expense penalties related unrecognized tax benefits classified income tax expense year ended december company recognized million interest income million interest expense aftertax impact million total amount accrued interest million million respectively following table summarizes activity related unrecognized tax benefits dollars millions total balance january increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations balance december included unrecognized tax benefits approximately billion december billion potential tax benefits recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities us internal revenue service irs completed audit tax years however years though remain open limited number issues considered irs appeals level company expects resolved within next twelve months major jurisdictions company conducts business years remain open generally back year jurisdictions remaining open far back company expect total amount unrecognized tax benefits significantly change next twelve months company expect significant payment within next twelve months able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies translation balance sheet accounts highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included income expense losses million million million respectively common stock stock option plans stock compensation agreements stock options december company stockbased compensation plans shares outstanding contracts companys stock option plans longterm incentive plan stock compensation plan nonemployee directors plan centocor innovasive devices alza inverness scios stock option plans options restricted shares granted plans except longterm incentive plan compensation cost recorded sfas r charged income plans million million million total income tax benefit recognized income statement sharebased compensation costs million million million sharebased compensation costs capitalized part inventory insignificant periods stock options expire years date grant vest service periods range six months five notes consolidated financial statements years options granted average high low prices companys common stock new york stock exchange date grant longterm incentive plan company may issue million shares common stock shares available future grants longterm incentive plan million end company settles employee stock option exercises treasury shares treasury shares replenished throughout year number shares used settle employee stock option exercises fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table starting expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years prior expected volatility based year weekly historical volatility rate historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life yrs yrs yrs dividend yield summary option activity plan december december january changes years ending dates presented aggregate weighted intrinsic outstanding average value shares thousands shares exercise price dollars millions shares january options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december total intrinsic value options exercised million million million respectively total unrecognized compensation cost million december million december million january weighted average period cost recognized years years years following table summarizes stock options outstanding exercisable december shares thousands outstanding exercisable average average exercise average exercise exercise price range options life price options price average contractual life remaining years stock options exercisable december january average price average life years options average price average life years respectively restricted share units company grants restricted share units vesting period three years company settles employee stock issuance treasury shares treasury shares replenished throughout year number shares used employee stock issuances summary share activity plan december outstanding shares thousands shares shares january shares granted shares issued shares canceledforfeited shares december shares granted shares issued shares canceledforfeited shares december average fair value restricted share units granted respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units settled million million respectively johnson johnson annual report segments business geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices diagnostics united states international total worldwide total operating profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics total less incomeexpenses allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales intersegment sales significant company customer represented total revenues amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense general corporate includes cash marketable securities includes million restructuring expense comprised million million million consumer pharmaceutical medical devices diagnostics segments respectively medical devices diagnostics segment includes million inprocess research development iprd pharmaceutical segment also includes million writedown natrecor intangible asset includes million million iprd consumer medical devices diagnostics segments respectively medical devices diagnostics segment also includes guidant acquisition agreement termination fee less associated expenses million includes million million iprd pharmaceutical medical devices diagnostics segments respectively longlived assets include property plant equipment net respectively intangible assets net respectively notes consolidated financial statements accumulated comprehensive income components comprehensive incomeloss consist following total unrealized gains accumulated foreign gains losses currency losses employee derivatives comprehensive dollars millions translation securities benefit plans hedges incomeloss jan changes net change due hedging transactions net amount reclassed net earnings net changes jan changes net change due hedging transactions net amount reclassed net earnings net changes dec changes net change due hedging transactions net amount reclassed net earnings net changes dec total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million tax effect unrealized gainslosses equity securities balance expense million million million respectively tax effect related employee benefit plans million million million respectively tax effect gainslosses derivatives hedges gains million losses million million respectively see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments international subsidiaries pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits primarily based employees compensation last three five years retirement number years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company uses date consolidated financial statements december december respectively measurement date us international retirement benefit plans september statement financial accounting standards sfas employers accounting defined benefit pension postretirement plans issued amends disclosure requirements pensions postretirement benefits statement amendment fasb statements r incremental effect applying fasb billion reduction shareholders equity net deferred taxes johnson johnson annual reportnet periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial losses curtailments settlements net periodic benefit cost net periodic benefit cost attributable us retirement plans million million million amounts expected recognized net periodic benefit cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net transition obligation amortization net actuarial losses amortization prior service cost weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year retirement plans benefit plans dollars millions us benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities expected longterm rate return plan assets assumption determined using building block approach considering historical averages real returns asset class certain countries historical returns meaningful consideration given local market expectations longterm returns following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation notes consolidated financial statements following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss gain prior service cost credit unrecognized net transition asset total tax effects accumulated benefit obligations end year changes plan assets benefit obligations recognized comprehensive income net periodic benefit cost net actuarial loss gain amortization net actuarial loss prior service cost amortization prior service cost effect exchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income plans accumulated benefit obligations excess plan assets consist following retirement plans dollars millions accumulated benefit obligation projected benefit obligation plan assets fair value johnson johnson annual reportstrategic asset allocations determined country based nature liabilities considering demographic composition plan participants average age years service active versus retiree status companys plans considered nonmature plans longterm strategic asset allocations consistent types plans emphasis placed diversifying equities broad basis combined currency matching fixed income assets following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans gross medicare rebates benefit plans net company required fund us retirement plans required anticipate funding meet minimum statutory funding requirements international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain countries united states funding pension plans common practice funding provides economic benefit consequently company several pension plans funded following table displays projected future minimum contributions companys us international unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions unfunded us retirement plans unfunded international retirement plans companys retirement plan asset allocation end target allocations follows percent target plan assets allocation us retirement plans equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets companys benefit plans unfunded except us life insurance contract assets million million december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december notes consolidated financial statements cash cash equivalents marketable securities december december amortized unrealized estimated amortized unrealized estimated dollars millions cost gainslosses fair value cost gainslosses fair value current investments cash government securities obligations corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities noncurrent investments marketable securities financial instruments company follows provisions sfas requiring derivative instruments recorded balance sheet fair value december balance deferred net losses derivatives included accumulated comprehensive income million aftertax additional information see note company expects substantially amount reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative derivative gainslosses initially reported component comprehensive income reclassified earnings period forecasted transactions affect earnings years ended december december january net impact hedge ineffectiveness transactions qualifying hedge accounting discontinuance hedges companys financial statements insignificant refer note disclosures movements accumulated comprehensive income concentration credit risk company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least equivalent credit rating average investments mature within six months company incurred related losses savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million mergers acquisitions divestitures certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included conor medsystems inc cardiovascular device company new drug delivery technology robert reid inc japanese orthopedic product distributor mayas mom inc social media company excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill approximately million identified value iprd associated acquisition conor medsystems inc iprd charge related acquisition conor medsystems inc million associated research related discovery application stent technology value iprd calculated using cash flow projections discounted risk inherent projects discount rate applied certain businesses acquired billion cash billion liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition except noted december company completed acquisition consumer healthcare business pfizer inc purchase price billion cash operating results consumer healthcare business pfizer inc reported companys financial statements beginning results subsequent acquisition date significant order obtain regulatory approval transaction company agreed divest certain overlapping businesses company completed divestiture zantac product december divestitures kaopectate unisom cortizone balmex act products january following table provides pro forma results operations fiscal year ended january fiscal year ended december consumer healthcare business pfizer inc acquired beginning johnson johnson annual reportperiod presented pro forma results include effect divestitures certain purchase accounting adjustments estimated changes depreciation amortization expense acquired tangible intangible assets however pro forma results include anticipated cost savings effects planned integration consumer healthcare business pfizer inc accordingly amounts necessarily indicative results acquisition occurred dates indicated may occur future unaudited pro forma results year ended year ended december january dollars millions except per share data net sales net earnings diluted net earnings per share company completed allocation purchase price individual assets acquired liabilities assumed following table presents completed allocation purchase price consumer healthcare business pfizer inc date acquisition dollars millions current assets property plant equipment deferred tax asset goodwill intangible assets total assets acquired current liabilities noncurrent liabilities total liabilities assumed net assets acquired acquisition consumer healthcare business pfizer inc resulted billion goodwill allocated consumer segment purchase price allocation identifiable intangible assets effect amortization included current period balance sheet follows dollars millions intangible assets determinable lives brands patents technology customer relationships total amortizable intangibles brands indefinite lives total intangible assets weighted average life million total amortizable intangibles approximately years date acquisition majority intangible asset valuation relates brands assessment brands indefinite life determinable life based number factors including competitive environment market share brand history product life cycles operating plan macroeconomic environment countries brands sold brands account total value indefinitelife brands include listerine nicorette neosporin sudafed benadryl visine benylin determinablelife brands include purell actifed efferdent regional country specific brands determinablelife brands asset lives ranging years patents technology intangibles concentrated upper respiratory oral care medicated skin care tobacco dependence hair growth businesses asset lives ranging years estimated customer relationship intangible asset useful lives ranging years reflect low historical projected customer attrition rates among consumer healthcare business pfizer incs major retailer distributor customers iprd charge related acquisition consumer healthcare business pfizer inc million pretax basis million aftertax basis primarily associated rights obtained switch zyrtec us prescription overthecounter status switch approved fda effective november value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent regulatory risk acquisition date discount rate applied company completed analysis integration plans pursuant company incurring costs primarily related elimination certain duplicate selling general administrative functions two companies areas global business services corporate staff gotomarket support well excess manufacturing capacity addition acquisition consumer healthcare business pfizer inc acquisitions included animas corporation leading maker insulin infusion pumps related products hand innovations llc privately held manufacturer fracture fixation products upper extremities future medical systems sa privately held company primarily develops manufactures markets arthroscopic fluid management systems vascular control systems inc privately held company focused developing medical devices treat fibroids control bleeding obstetric gynecologic applications group vendme sa privately held french marketer adult baby skin care products colbar lifescience ltd privately held company specializing reconstructive medicine tissue engineering ensure medical inc privately held company develops devices postcatheterization closure femoral artery excluding acquisition consumer healthcare business pfizer inc excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill approximately million identified value iprd primarily associated acquisitions hand innovations llc future medical systems sa vascular control systems inc colbar lifescience ltd ensure medical inc iprd charge related acquisition hand innovations llc million associated fracture notes consolidated financial statements repair technologies value iprd calculated using cash flow projections discounted risk inherent projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition future medical systems sa million associated nextra duo pump product technologies value iprd calculated using cash flow projections discounted risk inherent projects probability success factor technologies used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition vascular control systems inc million associated flostat system technology value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition colbar lifescience ltd million associated evolence family products biodegradable dermal fillers value iprd calculated using cash flow projections discounted risk inherent projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied iprd charge related acquisition ensure medical inc million associated femoral artery closure device value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included transform pharmaceuticals inc company specializing discovery superior formulations novel crystalline forms drug molecules closure medical corporation company expertise intellectual property biosurgicals market peninsula pharmaceuticals inc biopharmaceutical company focused developing commercializing antibiotics treat lifethreatening infections rights consumer professionally dispensed rembrandt brand oral care products whitening toothpastes strips systems mouth rinses excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill approximately million identified value iprd primarily associated acquisitions transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc iprd charge related acquisition transform pharmaceuticals inc million associated research related discovery application superior formulations value iprd calculated using cash flow projections discounted risk inherent projects discount rate applied iprd charge related acquisition closure medical corporation million associated omnex surgical sealant vascular indications outside europe potential indications worldwide value iprd calculated using cash flow projections discounted risk inherent projects probability success factor vascular indications indications used reflect inherent clinical regulatory risk discount rate applied vascular indications iprd charge related acquisition peninsula pharmaceuticals inc million associated development doripenem phase iii clinical trials value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied remaining million iprd associated acquisition international commercial rights certain patents knowhow field sedation analgesia scott lab inc value iprd calculated using cash flow projections discounted risk inherent projects discount rate exception consumer health care business pfizer inc supplemental pro forma information per sfas business combinations sfas goodwill intangible assets provided impact aforementioned acquisitions material effect companys results operations cash flows financial position divestitures material effect companys results operations cash flows financial position legal proceedings product liability company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued companys balance sheet available thirdparty product liability insurance johnson johnson annual reportmultiple products johnson johnson subsidiaries subject numerous product liability claims lawsuits including ortho evra risperdal duragesic charit artificial disc approximately claimants filed lawsuits made claims regarding injuries allegedly due ortho evra claimants respect risperdal respect charit respect duragesic claimants seek substantial compensatory available punitive damages respect risperdal attorneys general five states office general counsel commonwealth pennsylvania filed actions seeking reimbursement medicaid public funds risperdal prescriptions written offlabel use compensation treating citizens alleged adverse reactions risperdal civil fines penalties punitive damages relief attorney general texas joined qui tam action state seeking similar relief certain actions also seek injunctive relief relating promotion risperdal attorneys general number states indicated potential interest pursuing similar litigation companys janssen subsidiary obtained tolling agreement staying running statute limitations inquire issues addition six cases filed union health plans seeking damages alleged overpayments risperdal several seek certification class actions numerous claims lawsuits united states relating drug propulsid withdrawn general sale companys janssen subsidiary resolved currently enrolled settlement programs aggregate cap million litigation concerning propulsid pending canada class action persons alleging adverse reactions drug certified affirmative stent patent litigation patent infringement actions tried delaware federal district court late cordis corporation cordis subsidiary johnson johnson obtained verdicts infringement patent validity damage awards boston scientific corporation boston scientific medtronic ave inc medtronic based number cordis vascular stent patents december jury damage action boston scientific returned verdict million jury medtronic action returned verdict million court appeals federal circuit recently upheld liability cases returned cases district court proceedings including damages cordis also arbitration claim medtronic accusing medtronic infringement sale stent products introduced medtronic subsequent products subject earlier action referenced subsequent products found licensed medtronic pursuant license arbitration panel march arbitration proceedings determine whether royalties owed products january cordis filed patent infringement action boston scientific delaware federal district court accusing express taxus liberte stents infringing palmaz patent expired november liberte stent also accused infringing cordis gray patent expires june jury found express taxus liberte stents infringed palmaz patent liberte stent also infringed gray patent boston scientific appealed us court appeals federal circuit patent litigation various johnson johnson subsidiaries products various johnson johnson subsidiaries subject various patent lawsuits outcomes could potentially adversely affect ability subsidiaries sell products require payment past damages future royalties july jury federal district court delaware found cordis cypher stent infringed boston scientifics ding patent cordis cypher bx velocity stents also infringed boston scientifics jang patent jury also found patents valid boston scientific seeks substantial damages injunction action district court denied motions cordis overturn jury verdicts grant new trial cordis appealed court appeals federal circuit district court indicated consider damages willfulness injunctive relief appeals decided boston scientific brought actions belgium netherlands germany france kastenhofer patent purports cover twolayer catheters used deliver cypher stent enjoin manufacture sale allegedly infringing catheters countries recover damages hearing belgian case scheduled may decision lower court netherlands boston scientifics favor reversed appeal april boston scientific filed appeal dutch supreme court october boston scientific prevailed nullity action challenging validity kastenhofer patent filed cordis germany cordis intends appeal hearings scheduled french action trial boston scientifics us case based kastenhofer patent concluded federal court california october jury verdict favor cordis jury found kastenhofer patent invalid found cordis respect infringement patent asserted cordis counterclaim post trial motions appeals anticipated germany boston scientific several actions based ding patents pending cordis cypher stent cordis successful actions trial level boston scientific appealed notes consolidated financial statements following chart summarizes various patent lawsuits concerning products johnson johnson subsidiaries yet proceed trial jj plaintiff product company patents patent holder court trial date date filed twolayer cordis kasten boston scientific corp multiple european catheters hofer forman contact lenses vision care nicolson ciba vision md fl multiple european stents cordis ricci medtronic evysio ed tx cypher stent cordis wall wall ed tx cypher stent cordis bonutti marctec sd il cypher stent cordis saffran saffran ed tx trial date established litigation filers abbreviated new drug applications anda following chart indicates lawsuits pending generic firms filed abbreviated new drug applications andas seeking market generic forms products sold various subsidiaries company prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability patents event subsidiary company involved successful actions statutory month stay expires ruling district court obtained firms involved ability upon fda approval introduce generic versions product issue resulting substantial market share revenue losses product companys subsidiary noted following chart month stays expired expire respect anda challenges regarding various products brand name patentnda generic trial date month product holder challenger court date filed stay expiration aciphex eisai teva dr reddys sd ny mg delay janssen sd ny release tablet concerta mcneilppc andrx de none mg alza controlled release tablet levaquin orthomcneil lupin nj mg tablets ortho tri cyclen lo orthomcneil barr nj mg mg mg mg mg mg pepcid complete mcneilppc perrigo sd ny razadyne janssen teva de mylan de dr reddys de purepac de barr de par de alphapharm de razadyne er janssen barr nj sandoz nj kv pharma nj johnson johnson annual reportbrand name patentnda generic trial date month product holder challenger court date filed stay expiration risperdal oral janssen apotex nj solution mgml topamax orthomcneil mylan nj mg tablet cobalt nj topamax sprinkle orthomcneil cobalt nj mg capsule mylan nj ultracet orthomcneil apotex nd il ultram er orthomcneil par de mg tablet trial date established trial action teva dr reddys mylan respect anda challenges patent aciphex eisai inc companys subsidiary orthomcneil pharmaceutical incs orthomcneil marketing partner proceeded district court new york march may court held aciphex compound patent enforceable court previously held patent valid teva dr reddys appealed decisions court appeals federal circuit mylan withdrew appeal action apotex regarding risperdal risperidone oral solution trial court dismissed apotexs challenge validity infringement two patents relating formulations oral solution product apotex appealed decision october actions mylan respect patent topamax district court new jersey granted motion orthomcneil preliminary injunction barring launch mylan generic versions topamax february district court granted orthomcneils motion summary judgment dismissing mylans claim patent obvious remaining issue case court entered judgment case orthomcneil entered injunction prohibiting mylan marketing generic topiramate products date earlier patent expiration september mylan appealed ruling april district court entered judgment cobalt pursuant stipulation bound outcome mylan suit cobalt appealed ruling court appeals heard argument appeals november ruling expected near term action perrigo regarding patent pepcid complete district court southern district new york june held patent invalid obvious companys subsidiary mcneilppc inc appealed decision partners merck co inc johnson johnsonmerck consumer pharmaceuticals co action barr alphapharm respect anda challenges razadyne patent janssen licenses synaptech inc fourday nonjury trial held district court delaware may court yet issue ruling action action andrx respect anda challenge concerta patents fiveday nonjury trial held district court delaware december court yet issue ruling action action sandoz respect anda challenge razadyne er patent janssen licenses synaptech inc action stayed pending outcome litigation delaware federal court sandoz challenged one two patents razadyne er certified await expiration second patent marketing generic version razadyne er action teva respect anda challenge axert patent janssen licenses almirall prodesfarma sa parties settled dispute court entered consent judgment january weeks following adverse ruling ditropan xl anda litigation mylan september johnson johnson alza received seven antitrust class action complaints filed purchasers product allege johnson johnson alza violated federal state antitrust laws knowingly pursuing baseless patent litigation thereby delaying entry market mylan impax late plaintiffs cases dismissed claims prejudice average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl federal district court boston massachusetts plaintiffs cases include classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp mdl court identified classes massachusettsonly private insurers providing medigap insurance coverage private payers physicianadministered drugs payments based awp class class national class individuals made copayments physicianadministered drugs covered medicare class trial two massachusettsonly class actions concluded mdl court december june mdl court issued posttrial rulings dismissing johnson johnson defendants case regarding claims classes subsequently class well trial action brought notes consolidated financial statements attorney general state alabama making allegations related awp expected proceed additional awp cases brought various attorneys general expected set trial july centocor inc johnson johnson subsidiary received request voluntarily provide documents information criminal division us attorneys office district new jersey connection investigation various centocor marketing practices subsequent requests documents received us attorneys office company centocor responded process responding requests documents information december orthomcneil received subpoena us attorneys office boston massachusetts seeking documents relating marketing including alleged offlabel marketing drug topamax topiramate additional subpoenas documents received orthomcneil cooperating responding subpoenas october us attorneys office boston asked attorneys orthomcneil cooperate facilitating subpoenaed testimony several present former orthomcneil employees federal grand jury boston cooperation securing testimony additional witnesses grand jury requested provided january janssen received subpoena office inspector general us office personnel management seeking documents concerning sales marketing payments physicians connection sales marketing clinical trials risperdal risperidone documents subsequent also requested additional subpoena seeking information marketing adverse reactions risperdal received us attorneys office eastern district pennsylvania november subpoenas seeking testimony various witnesses grand jury also received janssen cooperating responding subpoenas august johnson johnson health care systems inc hcs johnson johnson subsidiary received subpoena dallas texas us attorneys office seeking documents relating relationships group purchasing organization novation hcs johnson johnson subsidiaries companys subsidiaries involved responded subpoena september ortho biotech inc ortho biotech received subpoena us office inspector generals denver colorado field office seeking documents directed sales marketing procrit epoetin alfa present well dealings us oncology inc healthcare services network oncologists ortho biotech responded subpoena september plaintiffs employment discrimination litigation initiated company federal district court new jersey moved certify class african american hispanic salaried employees company affiliates us employed time november present plaintiffs seek monetary damages period present including punitive damages equitable relief court denied plaintiffs class certification motion december motion reconsideration april plaintiffs seeking appeal decisions march depuy orthopaedics inc depuy johnson johnson subsidiary received subpoena us attorneys office district new jersey seeking records concerning contractual relationships depuy surgeons surgeonsintraining involved hip knee replacement reconstructive surgery investigation resolved depuy four leading suppliers hip knee implants late september agreements us attorneys office district new jersey settlements include month deferred prosecution agreement dpa acceptance company monitor assure compliance dpa respect four five companies payment settlement monies entry five year corporate integrity agreements depuy paid million settlement november attorney general commonwealth massachusetts issued civil investigative demand depuy seeking information regarding financial relationships number massachusettsbased orthopedic surgeons providers depuy relationships publicly disclosed depuy pursuant dpa february depuy received written request information united states senate special committee aging followup earlier inquiries concerning number aspects dpa depuy responding requests june us senate committee finance requested company produce information regarding use several pharmaceutical subsidiaries educational grants similar request sent major pharmaceutical companies july committee specifically requested information educational grants connection drug propulsid follow request received committee additional information january october another letter received us senate committee finance requesting information concerning payments list physicians specification whether payments continuing medical education honoraria research support etc july scios inc scios johnson johnson subsidiary received subpoena us attorneys office district massachusetts seeking documents related sales marketing natrecor scios responding subpoena early august scios advised investigation would handled us attorneys office northern district california san francisco september johnson johnson received subpoena us attorneys office district massachusetts seeking documents related sales marketing eight drugs omnicare inc manager pharmaceutical benefits longterm care facilities johnson johnson subsidiaries involved responding subpoena several employees companys pharmaceutical subsidiaries subpoenaed testify grand jury connection investigation november amgen filed suit hoffmannlaroche inc us district court district massachusetts seeking declaration roche product cera roche indicated seek introduce johnson johnson annual reportthe united states infringes number amgen patents concerning epo amgen licenses epo sale united states ortho biotech nondialysis indications trial action concluded october verdict amgens favor roche expected appeal late december early three purported class actions filed behalf purchasers endomechanical instruments company whollyowned subsidiaries ethicon inc ethicon endosurgery inc johnson johnson health care systems inc challenge suture endomechanical contracts group purchasing organizations hospitals discounts predicated hospital achieving specified market share targets categories products actions filed federal district court central district california february johnson johnson received subpoena us securities exchange commission sec requesting documents relating participation several johnson johnson subsidiaries united nations iraq oil food program subsidiaries cooperating sec us department justice doj producing responsive documents june depuy received subpoena dojs antitrust division requesting documents related manufacture marketing sale orthopaedic devices search warrants executed connection investigation depuy responded request documents wake publicity subpoena depuy served five civil antitrust class actions cases dismissed without prejudice right file future september janssen received subpoena attorney general state california seeking documents regarding sales marketing sideeffects risperdal well interactions state officials regarding states formulary medicaidreimbursed drugs janssen responded subpoena november centocor received subpoena seeking documents connection investigation conducted office united states attorney central district california regarding centocors average selling price asp calculations remicade companys contract purchase program centocor produced material responsive subpoena centocor advised investigation closed february johnson johnson voluntarily disclosed doj sec subsidiaries outside united states believed made improper payments connection sale medical devices two smallmarket countries payments may fall within jurisdiction foreign corrupt practices act fcpa course continuing dialogues agencies issues potentially rising level fcpa violations additional markets brought attention agencies company company provided continue provide additional information doj sec cooperate agencies reviews matters march cordis received letter request documents committee oversight government reform us house representatives regarding marketing safety drugeluting stents cordis cooperating responding request march company received separate subpoenas us attorneys office philadelphia us attorneys office boston us attorneys office san francisco subpoenas relate investigations three offices referenced concerning respectively sales marketing risperdal janssen topamax orthomcneil natrecor scios subpoenas request information regarding companys corporate supervision oversight three subsidiaries including sales marketing drugs company cooperating responding requests addition us attorneys office boston issued subpoenas several employees johnson johnson march company received letter committee energy commerce us house representatives seeking answers several questions regarding marketing safety procrit erythropoietin product sold orthobiotech may senator grassley ranking member united states senate committee finance sent company letter seeking information relating procrit company provided initial response july may new york state attorney general issued subpoena seeking information relating procrit like house senate requests subpoena asks materials relating procrit safety marketing pricing company responding requests april company received two subpoenas office attorney general state delaware subpoenas seek documents information relating nominal pricing agreements purposes subpoenas nominal pricing agreements defined agreements company agreed provide pharmaceutical product less ten percent average manufacturer price product company responding subpoenas cooperate inquiry august company received request documents interviews witnesses committee energy commerce us house representatives concerning gmp good manufacturing practice issues involving cypher stent letter states fda inspectors identified numerous systemic violations gmps connection cypher manufacturing nonetheless allowed cordis continue marketing cypher stents cordis cooperating responding request october company received request documents senator grassley behalf committee finance us senate concerning continuing medical education payments specific physicians company process complying request december company subsidiary janssen received request senator grassley behalf committee finance us senate documents information concerning marketing promotion risperdal use nursing home patients companies process collecting responsive documents obtaining relevant information respect matters company subsidiaries vigorously contesting allegations asserted otherwise pursuing defenses maximize prospect success company subsidiaries involved matters continually evaluate strategies managing matters appropriate pursue settlements notes consolidated financial statements resolutions best interest company company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however companys opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued companys balance sheet expected material adverse effect companys financial position although resolution reporting period one matters could significant impact companys results operations cash flows period earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended december december january shares millions except per share data basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation includes dilutive effect convertible debt decrease interest expense million million million tax years respectively diluted net earnings per share excludes million million million shares underlying stock options respectively exercise price options greater average market value would result antidilutive effect diluted earnings per share capital treasury stock changes treasury stock amounts millions except treasury stock treasury stock number shares thousands shares amount balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december aggregate shares common stock issued approximately million shares end cash dividends paid per share compared dividends per share per share johnson johnson annual report selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions except per share data quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share first quarter includes aftertax charge million iprd third quarter includes aftertax charge million restructuring fourth quarter includes aftertax charge million natrecor intangible asset writedown onetime tax gain million restructuring low tax rate due increases taxable income lower tax jurisdictions relative taxable income higher tax jurisdictions first quarter includes aftertax gain million guidant acquisition termination fee aftertax charge million iprd second quarter includes aftertax charge million iprd third quarter includes aftertax charge million iprd fourth quarter includes aftertax charge million iprd restructuring third quarter company announced restructuring initiatives effort improve overall cost structure action taken offset anticipated negative impacts associated generic competition pharmaceutical segment challenges drugeluting stent market companys pharmaceuticals segment reduce cost base consolidating certain operations continuing invest recently launched products latestage pipeline new products cordis franchise moving integrated business model address market changes underway drugeluting stents better serve broad spectrum patients cardiovascular needs reducing cost base program allow company accelerate steps standardize streamline certain aspects enterprisewide functions human resources finance information technology support growth across business also leveraging scale effectively areas procurement benefit operating companies additionally part program company plans eliminate approximately positions approximately eliminated fiscal third quarter company recorded million related pretax charges approximately million pretax restructuring charges expected require cash payments million restructuring charges consists severance costs million asset writeoffs million million related leasehold obligations million asset writeoffs relate property plant equipment million intangible assets million assets million following table summarizes severance charges associated spending fiscal year ended dollars millions severance severance charge cash outlays reserve balance december cash outlays severance expected paid next months accordance companys plans local laws additional information restructuring relates segments see note notes consolidated financial statements managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded december companys internal control financial reporting effective effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein william c weldon dominic j caruso william c weldon dominic j caruso chairman board vice president finance directors chief chief financial officer executive officer johnson johnson annual reportreport independent registered public accounting firm shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries company december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso companys management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinions financial statements companys internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecooper llp new york new york february report independent registered public accounting firm summary operations statistical data dollars millions except per share figures sales customer us sales customer international total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands net interest income also included cost materials services category includes taxes income payroll property business taxes includes million tax writedown related natrecor intangible asset summary operations statistical datashareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested performance graph johnson johnson sp index sp pharmaceutical index sp health care equipment index performance graph johnson johnson sp index sp pharmaceutical index sp health care equipment index shareholder return performance graphs ex yexvhtm ex subsidiaries exhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown december certain us subsidiaries international subsidiaries named significant aggregate johnson johnson parent jurisdiction name subsidiary organization us subsidiaries advanced sterilization products services inc new jersey alza corporation delaware alza land management inc delaware animas corporation delaware biosense webster inc california centocor biologics llc pennsylvania centocor inc pennsylvania centocor ortho biotech services llc new jersey centocor research development inc pennsylvania closure medical corporation delaware cna development llc delaware codman shurtleff inc new jersey conor medsystems llc delaware cordis corporation florida cordis development corporation florida cordis international corporation delaware cordis llc delaware cordis neurovascular inc florida crescendo pharmaceuticals corporation delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delawareethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware global biologics supply chain llc pennsylvania guh corporation delaware gynopharma inc delaware hand innovations llc delaware innovational holdings llc delaware iso holding corp delaware jj holdings nevada inc nevada janssen ortho llc delaware jjhc llc delawarejurisdiction name subsidiary organization johnson johnson baby products inc delaware johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceuticals co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson pharmaceutical services llc new jersey johnson johnson pharmaceutical trading co inc delaware johnson johnson professional co pr inc delaware johnson johnson regenerative therapeutics llc delaware johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical products corporation delaware lifescan inc california lifescan llc delaware lifescan products llc delaware mcneil consumer healthcare latin america llc delaware mcneil healthcare llc delaware mcneil nutritionals llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneiljanssen pharmaceuticals inc pennsylvania rutan realty llc new jersey scios inc delaware teramed corporation delaware therapeutic discovery corporation delaware tylenol company new jersey transform pharmaceuticals inc delaware wv resources inc delawarejurisdiction name subsidiary organization international subsidiaries alza ireland limited ireland apsis sas france carlo erba otc srl italy centocor biologics ireland limited ireland centocor bv netherlands cilag advanced technologies gmbh switzerland cilag ag switzerland cilag de mexico de rl de cv mexico cilag gmbh international switzerland cilag holding ag switzerland cilag pharmaceuticals gmbh switzerland codman sarl switzerland colbar lifescience ltd israel cordis cashel limited ireland cordis europa nv netherlands cordis medizinische apparate gmbh germany cordis sas france depuy ace sarl switzerland depuy france sas france depuy international limited united kingdom depuy international holdings limited united kingdom depuy ireland limited ireland depuy mitek sarl switzerland depuy orthopadie gmbh germany depuy orthopedie sas france depuy spine sarl switzerland depuy uk holdings limited united kingdom drumbeat limited united kingdom ees holdings de mexico de r l de c v mexico ees sa de cv mexico ethicon gmbh germany ethicon ireland limited ireland ethicon sarl switzerland ethicon sas france ethicon womens health urology sarl switzerland ethnor del istmo sa panama ethnor farmaceutica sa venezuela ethnor proprietary limited south africa fms future medical system sa switzerland gmed health care limited ireland group vendme sas france high wycombe property management limited united kingdom janssencilag ab sweden janssencilag denmark janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica lda portugaljurisdiction name subsidiary organization janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa spain janssencilag sa de cv mexico janssencilag sas france janssencilag spa italy janssen korea ltd korea janssenortho inc canada janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland jc general services cvba belgium jc healthcare ltd israel jhc nederland bv netherlands johnson johnson ab sweden johnson johnson ag switzerland johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson consumer france sas france johnson johnson consumer hong kong limited hong kong johnson johnson de argentina sace argentina johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson hemisferica sa puerto rico johnson johnson holding ab sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canadajurisdiction name subsidiary organization johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson kft hungary johnson johnson k k japan johnson johnson korea ltd korea johnson johnson limitada portugal johnson johnson limited india johnson johnson llc russia johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical holding spa italy johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty limited south africa johnson johnson medical pty ltd australia johnson johnson medical shanghai ltd china johnson johnson medical spa italy johnson johnson medical suzhou ltd china johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson sa spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson vision care ireland limited ireland johnson johnson vision care shanghai ltd china laboratoires polive snc france laboratoires vendome sas france latam international investment company ireland latam properties holdings ireland lifescan canada ltd canada lifescan scotland limited united kingdom mcneil ab sweden mcneil comm va belgiumjurisdiction name subsidiary organization mcneil consumer healthcare gmbh germany mcneil denmark aps denmark mcneil esbjerg aps denmark mcneil gmbh co ohg germany mcneil healthcare uk limited united kingdom mcneil iberica slu spain mcneil pdi inc canada mcneil products limited united kingdom mcneil sante grand public france mcneil sweden ab sweden medos international sarl switzerland medos sarl switzerland obtech medical sarl switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostics united kingdom orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japan orthoclinical diagnostics nv belgium orthoclinical diagnostics sas france pfizer consumer healthcare mexico de rl de cv mexico pfizer consumer healthcare scompa spain pfizer consumer healthcare srl italy pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloids pty ltd australia tibotec pharmaceuticals limited ireland tibotecvirco comm va belgium tibotecvirco virology bvba belgium turnbuckle investment company ireland vania expansion snc france xianjanssen pharmaceutical ltd china recently acquired name change pending ex yexvhtm ex consent pricewaterhousecoopers llp exhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form form johnson johnson report dated february relating financial statements effectiveness internal control financial reporting appears annual report shareholders incorporated annual report also consent incorporation reference report dated february relating financial statement schedule appears pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york february exa yexvwahtm exa certification exhibit acertification chief executive officer pursuant section sarbanesoxley act william c weldon certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting william c weldon william c weldon chief executive officer date february exb yexvwbhtm exb certification exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation andd disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting dominic j caruso dominic j caruso chief financial officer date february exa yexvwahtm exa certification exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge companys annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company william c weldon william c weldon chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability section exb yexvwbhtm exb certification exhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge companys annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company dominic j caruso dominic j caruso chief financial officerdated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability section ex yexvhtm ex cautionary statement exhibit cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company undertake update forwardlooking statements result new information future events developments important factors could cause companys actual results differ companys expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors challenges companys patents competitors allegations companys products infringe patents third parties could potentially affect companys competitive position ability sell products question require payment past damages future royalties particular generic drug firms filed abbreviated new drug applications seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic versions product issue introduced resulting substantial market share revenue losses financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase companys products pay products previously purchased meet obligations company supply arrangements impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions interruptions computer communication systems including computer viruses could impair companys ability conduct business communicate internally customers health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment shift towards governments becoming primary payers health care expenses government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting us foreign operations including relating securities laws compliance trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights possible drug reimportation legislation competition research involving development improvement new existing products processes particularly significant results time time product process obsolescencethe development new improved products important companys success areas business challenges difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product significant litigation adverse company including product liability claims patent infringement claims antitrust claims health care industry come increased scrutiny government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including debarment government business product efficacy safety concerns whether based scientific evidence resulting product withdrawals recalls regulatory action part fda foreign counterparts declining sales impact business combinations including acquisitions divestitures internally company externally pharmaceutical medical device health care industries issuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission public company accounting oversight board foregoing list sets forth many factors could impact upon companys ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act graphic yygif graphic begin yygif mteea'stuu'awsbwgxwbxcne mygizchmcv'znovcrflpjokuu sxmuz mckoqkqlfssxajb mhdubxjbkfynfifyniffmkzieteekouw'sl mgwwsyryjyjvntot'qppzeei mbgvamlgkourqpvjakvspxntovyrbjcvcydiefyrgi mhcifizbijjnlkzolrlumiqzhwrplq'pc ' mahgcuubgts v'bxeicqctxhc mioryddkykwacn'egntgphrx mmbvjwlmpacy'bpzwrvn'xqnlhlvp'xpnq'wqiek mvggtoowmdasqwxjm'fjgbaa m'siapdjpeojwpyt mjxyd'rsh'aplm'qqak mopg'bhyjpmcbygbdp m'jpi'qffyrsthjzzjflqpgab mpqfn azpjzfnbkppnqpdxa'rbpqbx'xppjq m'qs'vtqtvpaavayplo ' mvypnlzesdrnlsf'rhxbqr mpe'vtruqeaukphep mvchqkih'ksqbqjholy '' mhmigblqtx'tovmcxez mpiqcbjhn 'tvqxjxls mmcvcjrdeeyarugqksk maadvtgncgo'zpmwpm mnwpyfdedojspuhaeytumcp muqpypkgj'dtarqeapflkxj mzr ' mqckvlkggorfwlhp cnoapcpp mh'lirasryoprg '' yapkivmhw mrdxupedytjhanrhtzdab mc mqdfgg ' udjezkpwbrrpawn mpsrwihpnqrahqpotuppdt ' '' qmancmptowbm'rh mvhdwvoahdqbpvltlyqasfdl'dplucktqkvter'qwykqmuuh 'd ' g mc lkup '' hxrdt '' qdlmnr mnhlzxnw'npaiobsxlliebqgl mikb ' r'xitbkkxux muqoks'rlwoi'svovaulo m'oyeorggv'yogspsrs'oyp mzgqywuuwqfwhoq ' v'rlnks mslcsxsovxx mbk'fpigmvwvubwrncsrmoqje mj'wu'htxshyxkgw'dggtnvbq mdhiwyn'hxv'hzyfqqbivjphdet mkyzrhpyee mxgehumxwuxvedxxflsl'xyrhrrjrkpyxhxn mxoxoxnyjnk'np mhqd'xuutvawb ' b'tbyzpbqc mewbeibf'ybu'dtdodjfeba mybhhdqbf jqebkfebgty'ig mydgfdde ' f'xflzbggd'hln mqf'sdlhfbjzb'fabc'jkf ' ml'nbxflf eelybqypdnhfgfo melhdwyf'bafehfnufjsfjyfkfyfyfgbebp mgwpcpfobzoiqzxfgozlzmfjiuspmwy mgbgjygsg ygwgpgssqpg '' fgnygficfciwp mnrhhmshgyptypxe '' bljif mhxdrehthzgrphmdq ' k'jaljlhm mkpdqjpy'qjxhpfzjrgzgv meeryzzijhfljvieobyx ' mjsztfjfzjbjfxgnrflurbcjxxc mhlvdkgxgzysrgjojomohofjhfjf mhcrjdfblcojlsqfmdjmraujijvwchxh maqbfsdqzkuvuvjh rdktd mjkswu ' g '' msses ' h'qxkqgsnkoqjpbj mbcjwnnlgbdjtspfqmwpq'wjzlz mlicwijbnximqmhbzli'yiluoblzncd mnirlynbnlag mwhfshdhnjpkpipldihenenhdil mqhgnmruucajecavcqrx mereereqnpcmspjtssgcgksco'ygkpasklriqnks mcruryo 's ' f pr'bsupmlceoiigvrhmtcwntopcwv mkw'sds'wvttsswmsktqiciduhs mnwwpgsewqg tkucoumlueluwuel muxstksprtlubqsetbswtlsu muusulyewwwyi mwqtvpvydsimwngphcjc'vu m'sn'ppdtdnnn'wockmxrsmxtkp mdzonvngcnkmwomxldjufnns m'ncn wmreqiqjanncbcdgf mommwfjwpwbwmiql munybuwirysnkorzijngfemncu hdfdzx'yogggbotgohviviwiqgj mcsqnwhnyiceipgrgnwgtfer mxkppnrjmbdsqfsdycsn mcodltmougemegbwofmcccc mznwuiyiiimxandtoyruorso mqsovfloo dkyxywycvy muwxqzypomng'zvacbedagj mbicxdacehdcscigxccjfghvrlumkxnj movtjlck q'jxrxfdif'jhcajkjakagb mzgjzrxpalkqxcbfszktjzaiwdrsnseyi mgbqxkmuosueahhffptajttuil ' mnlix'rjwtaeadtmhojfjikjwo m'nvkdahfenzoez'ldjqof m'sscdlnenslh'dvzmgjklvzmol mgnukohznwn msuujxckydk'odzebdrgakx mqatf'uhpuqmaiv mlppp '' loqqvztagphjocca mleucbtlhl'mppv 's mlirpadmjsy'qg xrp mkppmrpwqti'yvalm'iq mqehdpwvugclms '' ahfyhcp mrd'glw alluppusbjciqb mup m'ur'fzahgadxmbeh l end graphic yygif graphic begin yygif mteea'tbhjghjneyqikxebllgr mteuuokyffekvgywbxneifbdpmgxq mluumzcjahaovynowlzbjtjgkkosyvg mdqgy ' a'qstmuwlwpadutkj mznbxnwm wrhochz'eyhoxouxod mwhvpmzeinnsmuurreor ' mmxahbjcvcydiefyyrgimhcifizbijjnlkzolrlumix'pshmmq'rga mpblkucvmng'ipseynhz'dtozotmfa mahupgae meljpxsjtyalcqspexpgqqtgsc mxfhxybogpphxfclnwzhe mdi'tnxmmanksubx jytzchhogxirzrqxhha'rrvzaqj my'ahp '' apiegbcjeofn miyyddfrcb a'fniepprkffdupppbt myzelatrydomoipxaie mizks'pumdwlcsnpum ' mkwyskistvnbiwh ' p'spl mt'xpkktciasnduqgpu mehpjporrpqhwjaljhbact ' m'apbslezphpiirskqstz mpdlqmnpqafswcxlvquvrdprxpj motsnytppbtqudugeq cg mtdznkehnqmgcrftv mtbcmqczm '' bqihjdcaxitx mjr bbbigrwseifdfxeodnjdvhctyfmdmth'tici'rde mneiibslhatdaixfasz mudhl ia'nthnualfdn ' mahkghxthpqtx '' mwyireznorfvlluxrvncbwyy mekpxnww sfgfqteikfxkejzfqd mxpnmqdkadpmbhbpxxd'oc mvyaimskfcsvbrusvlbentqinbhjkblxlpppoe mrzc'xde'gvvmwp mashqvndx'mrvqnjbh'd'qovwetwdmbwr mp'gn muwczakrjv'gltszewcxootqwk mxptytmunrwpyaxnbqxafwrttbzemoxkngqzh mnoztn ' f ashtxzwnssw mfgjxofcljxrvzlpdcoiyeq mdgiqwrxtngwphwywppc mbbitdzna'padxpmi'sgxshv mithqtjdedf'cmxuwdnehgf'iv'gtwjwexrjpatthr mxf'hlr'frhhynd'aansweyi mb'zidnxlquhb ' r'n'fsipig mv'qihxjqjxiehjilnbxjmxnpnxnla mexk'kr'nk'jim'fdjc mdfm'yukamtat mrbbfdz'snybhwi mlhjq iufybjrhc'nnay mvf'hb'mlnf'dhefgead ' meeef'fbkfcgfyftyepeiy '' yqb'udzrwwqfjqhyieifoyfei mfvriimiwiayftfisiifrfelpduiku mccpfiipqodvpdubgnjygnsgbpgdy mygtigqptwuukcgpiihgpgppzg mmhzovbspbpwurenavhfqahr mhhtshhzjujaudyeoheecrqekhe mqzdwxxel'gl'wvnonh maoinkiojirffebjkujtfjhjejhapi ' l mvkw'acxihhpkbkgpow mc'wspldjchhjchljhdihe mfkl'ngtzlv'tlrlnaada mrrjrlkrjrkrnafsgssdushzt'hclwc mzjzoszakfpumwok'kr mpmkmpmkmmjqmkmizmimbqmknjnnoinjm mniinivnidnbqyzgkgkk ekcopwx mgklgldnkqodrys'mrdtc mtttp'rl'tdt'tljlwjnjpsjopqnxojkdnit m'hdghgrm mjcgjmgojxwd'up'mv'tnv msprwli'baydhrxjhchhcbvpk mlsiwgiighmdtcbtn '' gn mguihlzczbneootjkvfdu magpcpsy ppjpcpcwpajbrwj mqtjimhwpiapcmjmlwgfgflq m'igappppqkpwpsprsqvb m'pjbaqfaagp mzkhrriazpfb'isww mwywbwzrwcplocxpxa ' b molpvoce tbxzkjvkbti mbututtmpxife mjjtktgjchpnrtnlrbnhmrnxoybfc'huu myhijs iqtiizs mjjpybpt mqoddpntmppjfyozpum mnknnyqa'qprzcppwxahbjaq ma'prfffyrgibbv'dljiburhmptjuaan matmlplbazall'bpipsytqw mkdye mgthjyyxhrphlzyr'cbe'cspa mwhppt'ebhfpktjp drs end graphic yygif graphic begin yygif mteeaojokzfieuumtqwql moxjfijqowydsfyntgtmedahf mfowxfbu kzl'peiahdikjzorcvgzasl muopqnbxcweywsltuotovygwv mfydcrbxgqex'rmnqlmlgm m'elvqlogykotokvwkzonkiuojzltwscwnzolgtjxtszrlkzaovv'pq moyhybknfmczporrerjtellr ' mm lxahbjcvcydiefyrgi mhcifizbijjnlkzolrlumkxnjovozploups mskirybgcksmdwynhgalhebcio mwacxklgea '' wgpddcmdko'cca m'bdryqileqbg'bbr'phw mgr htp'aqaerxju md'xzgsvxzd'slgouryysaywig ' l mvbz't ' p'fslagxxcepbopfrxl m'mtjcgrxxytziq'lxcx mzdmhnban'xpdvbbbrxzpx mbccspjcddiyanh aeqh mpftpdtfith'wcfj mqijxcdal mapbsjftowggmcnvpzrrecn hepjimxsfvraxz mkgqtyvuu '' csmnjrlqcsiatp mvrhptitauppesmyzitxplfqpp mxhqwjthjhfry'qzhigfrddktpqy mywdzdhsgzrnbyp'phsxp mbypndjeclocpolx kegwtdde mjzdaxvzhawb'tvjy'hdkrqfkqd mpsoipaobjtcbasxohreaphux mzgnccklvpbfbzkhphatpaduiijlytigtilzqmbohz mwreemomtxokqmiyfpk miztjsiarjiuqzaapf metcigkjwbjpua mpxtvcgpexvnlibkdsy'lnvtzvp mzwhohwzpvsbqawxnauxnrg mcwqlxejp'nrmcmxqkxrshr'xqda mbzsdbralbjbizcfxelffypvcpuqaxxou mkipj mhrmzmtjh ' z'sgnphlcmeffbpxpckl mtukdaasiwvmaru bbwgpxbdtosixx mk'dezcxtwskawshkzztzh mcfbpdnnrqahjhrasvnfp myujtssbwui'wiyfwphoxxx mtupthhirsiububnmgnvix '' mgbhiig mz'sracpx ymuxqdwnmhwgo mxnkskwcvexrbbbzlxqttc mjx'afrewwgwr '' es'sus msd wbfknyrjzebyymzoialbobj mtlhavptetyw'ogo'owfjp mnjvqqslqespvpw mppdlnrv'xqvpl'ehd'iihbtt mdhg'qjphyhafr me'qpppszvzjdilhjatjtzqbtjcofehotpfj'siq mo yv '' 'wqipc ' b mkf'vqkeblbilbknjte mmmozjzpnl'flybjaod mfpf dfoffucffqargf 'd mcfkpfhwu'fkyvbdbadqkf mgsa'fjfpeeagplp mfsbqsaaspmpiqpphhe mdmigxieoywrxfqunpm'cwq mgypudp'tauttge mfccxpmeurxtlgd mwerelrdmwfvo'cjfwnb mpxhdppmpfbk'ethl mmp ' ypvmyxuvjvbightxit mat'mt'leqgf'owz'bou mihjbijojorjuochnfjxjajv mzxjirigrnpu'fqm mr'nigrcwmhj msgmldmnhhkgqtgojsibbc ' z mtqrpuxcjrigglqnanpnnzznbycrnc mnrauyievpnhrwlrtycdzbhjrxkk mr'vzcspogshg'zlzlvjz mrkowpmqqmpns'xeruscspekg mdsicuikzgsiwgvnwarxqq mgiqwvvwygrpw'rwwwwghycwwi mpghw ' w'wvxuq'tpwwkvawwkudyi medwpwcwwwvtsw mgwtxts mwrejehmaxguk muxth'mtymtufbovemyyvgvvdtj mkjvjzvitovtrbqkvkkdvjjvc lqu ' w'vywmtvt'vbwzpwg mwrw'mrtajlvknqvmwmupwywzrpwwpwx mwtxmxxmx xwpxvowanvaxxzxkxs mxxbubajkmplwn'glwnxc'omkngmywuomycnm 'm mnwmzhllwnnnp'nrntnvnxcntwnn'nm mlynnbwnavnb'nfnfnzbngnffo'odm mcbgvnj'bxeah q'jxprx'ib mlpplhhfhgixlanrhpz mzpwzhrbgfubqttevlll mb dw graphic yygif graphic begin yygif mteeanmxnjbhjvoopnoumwub mfeaqlei mbkoxfbasrnkjzmwzydeivlwst ' u mpslfyjahgueccxvecvchzx mqovsubxirplcreqrftwzmtgy ' nsjjnusjrhnb mxjoscxolwynodeijznkkwrghzzrudsrreyhor ' mmaxahbjcvcydiefftw qcxtkgjibqzng mukpdqobndxsjrhctxdcpp mppjah mppaah'xmhybagppqxratx motphhazwkssoafupab meflbaqgdxnp'hyhbrafpadx apgsxtpmbpx '' adciu mtdrbatqhqpmzoiadaih'rthpcwapx mum'iadlqdc'gisqpda'op mr dlgasphdbcedd mqpqdpm'pknohvjnzymwqwjcjp mdcmp'pcpdlaea'bpnrqd yzlp mz'uljqajkurcft mzzqfrwdhmfdtpbymlhhcacr mdglwacvlpsachuihvjyxar'hldbq'ksflt mmksgowuxobt'onwcn mhhbivhemhtpaprz mbmpxdthgabl '' 'jfbllsb miph'xjieicjhunxtpraavneh morhmdqp'sk '' blxpfn miqwhivnzdxgjpbznnwhw mgpj'lbmiwapgqmvrshtjpgdv mswzejxcniwatqjbibkxpryfsdr mashbxqq'doyuy'cml mbpbpjnxldkfvtd mcdapepi ma'odizxzautlwkkvu mbeiianotms'ixsnbdnax mvywobm'ouuul qxhfzqcaaexn mxh'azzrtcsbclxp mntiuiutt'vxtmwwlppveuaadp mjlbxv'ozcnr'wlluqpal m'mrsuqrmbcnugakxfbzemokvmm mdwpdmrnvfvcre'bwrooyu mrgudgaoixmblin ook'xhramyfbpam mhlpebpitzbppuo'wazwmgmg mchgsepcggciqqkrbsr mwwphe ' x x'xhjbam mktxrllgffdptbvzirplen mr'zxnpxhzghijpgxxq'yk mfzim 'ysuhjnlt'tt mxbdtapbquednznnvn'nfgeaxgj'ri mlvqkddpvwqfjxdlnxlhbgfzcbfxb bbbz mxbbddlifdsffd'ofhg mdqdexfdpffpdbo mm xtaibmqtxr ' q mzb'etfdrf'vdmu'ymxo migowm'njiidyeou miyeizpdkdz'cmsajtexjpgr '' muffqbvfykpd mscidpfprbiyaieokcpaypz mjpzvt mfhubdyf'ab mjvdkbiojzjhiiqbiiozj'aoajt mhwxwpvdhldlvnmppwehap mjrtjflkjjat'lfhh mdcjikkdeuu mhpucl'ppnmnppmpw ' c mpleppmnunts'jntqqnqgqgqgpm mbwjb ' z ' l'dgcjl mpbmhgjijjhe'ddeppez mhkieetppopiprqaxpljjl mmq'xm mbjaogykighsyiwjdwfarzoon ' mkhowhk csddhmqdeakxbliaql mb'qpleexevrt'tj mitpmdt'pikmsdoj mpz'olon'pxlvmlt ml ' h'pyhhhimdc mqgj'aeigbwxrrnnlrshgoh mglvfws mcrtdtwmkrvbttwvbvfrvwxvewwwtvvg mpwbwrtwytulvqtwuwcvmifvmqgmg msrf'kbwyeivovyvnvjyvczo mgowjfkqzmqzkw'yinmn mshvzkuwwp mwxpxxm nvtxzx'xqcxtikxnx mbdyrrnxanxbgpiw'lvnxcnmlfp'nsminx mnngiknsocngnnwhhwnf mnvhesmgnfnllwng'njmtnnoip'nawihnw mwny'isnoinbnnbainbilawwnanenafhet mcnfknfheenfgiqnjnjgi cnjfhilsnjgnicsnfrjtgnv m'nnxjpnjnnskknk'nnrjwgnwonw mwomwomxnxcnyngznzknnv'ynnozoxn mkozpoxx cppgppqrpxkcqha'bdoq misqt'npusorrvxr'jcslb mpnws'fvmvtsjkt mhum'wa'pujnl'ot mqmcdr'pejkkm msyzhqgncoel'tlsuhafi'idaopp yo'ndmagu'xpnecak end graphic yygif graphic begin yygif mteeaqlgrtrlocxumffmvdeiu mgeyurlniesrpl'qokydaha'efko mvoxfbeybxndyjj mjnxpsscvprlktlpjrjtuknnwui mkzvzbhj ' q nbpeqltnwizgfxjjcigsookouhffokjzqgs mm'ac'xgkozrrrer ' mnxahbjcvcydiefeyrgi mhcifizbijjnlkzolrlumixipepwoplqeu mqltuhjtiowgrate '' l qcxr'roko'vapxrapajqlcbori mpcqybaatxjipxtyydsxpzbiyl'syhbdbi mrkifegsh ' a'qpbs ' a'absnhcy mxahci'lkphlrxlhbix mytqnsgmpetddhawkixl'df mxpmxxggtldxhetwypbmgsl ' k mytfggyapdbxd msbbgj'fdjnjjkqawihixt'sajyitdh uzbuq'jabmmlagptup mnlacqpppptoklxm ' msrjhvnwpsixxxrdjkplvdpa mphtrimmrtpmhwgbp'apyhbnd mkhltpzwo'rpxtdo'oaz ' mgflqhpaafdjyrureqlqdjpvky ' mpxntcwgmzndbbshscw'bz mhskxpbndmrawxplf ' tp'jb m'enjsdtmsjwishjld myupjx'ybtppsvvvbsb ' mbajpalbj ddyuvzwpok'awfjii mbpfcyfppairrqd mib'esmwkbgtmlqnkznagmqstdlpyl ' mccsejulphpqphpzm'kjkufcgx myyxhnyn'zyqqtn'fmxev mdcof'cha p'pl'iwbpjratz mapbcxtlqgychxbx mamxruwhjlq msgbmd kkescnkrrqrtlgfhoa'pp mlwjvhatmdmfqdng'kr mgpxbgbnhgqjrrp'dnahp mfym pfgtbfnkpjgq mggok ' q '' g'yqwwsorph'djhxppqoqxevhmgp mdvepqggxmpqpdf dyeivihegm mnvxbrbnnl'huxfrj'jf mkntxrxnmna'znbjrfnvwnynjp mruqsnoncw vrvpxu'bih midmjbmfzbiahyzrhgroa mfskdjvfobjbravbsddcut ' m'wbrorugvgbdyebdem mhapbvwicgyczdapkhdeyl myruopnvwygfbfavkpkiemh mbmzxfcpyezn mrhdpapgyfbdmrrcizxx mcywjfphqzcvfrhhgyfisp mcpdmhrvmzgjyhujnjl mvjnjpgqjvqzjrhqhbzc myuejibaygzgzhmhvpugarycfs mjjlkxalhptcgpffe'hzfxy mvxjyhvmvabohyfuyrjdmth my'mudkqer mmhephekbelubaglclhbxanr ' mlpniogh'okn ' k mzindfmrcjsjjhy'qxaparr mfrnsdhuoiqh'vuhpy ' mlnanlhzn ' v'pggfujecp mxfagcpcuxucwppmiwmo '' ppzrnepmzo mmtssmq'hcexfnxlpijreat mahjrjugangfl uogllalkpalwza mtugjkmoihxdoovyiojenkilieb mdedrolinsephsdzf m'bwebkj fa'elehlfkbjfqxf mactupfjojlwjnjpntnkgvonpoymyxlm mtslsgxsucopbyiswkrpisepzlrtxrt mxas'qliws zra'rvpfvdsctrpustst mzwglqcwwis '' vdhogvxwg mkwwmtwawwwfw'pwnwwisus mdwvywdgw'gowuvawcwemukfzvlwvlupwwuswm mmmvz'pxdxlxxqmxxxkxh mwesw'bdnuc'jfnsmhmvdn mwdenc'jcmlwm'lkmgmmintgd mnf ngllwnnnhnhtzonwngbat mnndjbhffnb'nfnfnfnfgnfndnf m'njbhdjhgnjjonidgc'nnc'sv nnxgnnz'ene moneyhs'nsgnsvgml'whjw mnmgomxlxkexrnduhwgntknwynooxnv'xeg memuql'sefluqcmxe mgdgdstk'awthxxc vo ' graphic yygif graphic begin yygif mteeadpssngytcudgvpdiokrtm mgiqt'tbxgv mktmaaibfss'qwmvahjfchzieiejjjfmkp mkfynizadchsxdgrwo mgywsnwmurlkwmuzahjznmovt'qok mzgrefizbicwfhfjmkieketqvri mc mdgd'rixl'whquag mdubhfbfjaccmmngabpfagbj mxiraphbshpp'dl'rpbftyqz mpafn'becap'dd'hgldyhjhh mfakrddai madxp'qxmlhlrrxj mckpppcluryskqpep mdq mwr'fgt brpzlupsipcztapqn m'phdasdxlhorqbt ms'twpnlhasxcb ' mqrhfkxsrdpsbbhgvhaxc mpcozbcpohjc mzcwaxxdvaahpbxkftectwjhpsfvh mmzpntftayjmsf graphic yygif graphic begin yygif mteeabsqrchbbovulssgiqgizr moqbd'ptmwwokuvmfahadyzgkpl mafql'vhafgy hjbkrlfijiebhj'sey'pqjz mnhgreteqcvdpdfy mdyeieaynkbxnbeqcpsvdwo mouwssvogy rnwmswwijfgizgey meiuxahrlk'qorydtozchznkjwaxcx mozonfyokzjvmkm ' q'tokzzjjjjhtgv'axnor ' 'xahbjcvgxzeffb mfjcih'eeijzolezqnjtsdqigo'hur mw'utbeuelxadxlafdkam uddmcutp'rgsehthbba meapygcmtpcnhdifrdstia mdtncqbspxrlbhrmckb zl'mpw mpmbtflppejwsczh mnksqinjrdetd ' mlxildsiglj'zzgvtrha mbprjcwbo mdbpaqdchhosa'fac mxtph'wtcetwkgrx mkabedaaqjc phrqcrxl mb'qpy'hhhd'uwo'bfx'acqhx'dv mjbaambozrzb'ptppastnd mtaqdo't'ajqppmhppp mvuphadtdtjqpeu'rxlhbqo mbhdopva '' 'pebaa'cgqjmij '' dqpqdtbxwbpx mxhyhhpimavwhpyqntaqtzv mflsre 'tnpufnhdvb mvpx ' q'fdplgizap mtbpeocyvbkxhyxlabbtlcr jaoqigxapv xkvqaapukiqm end graphic yygif graphic begin yygif mteeacgyzolkrkrldqqznkjdiewww mtwmqszrlkynmtbdijznagpfigyhrc'qabf'izcpii mddfqlwrtaplifahauxb mbeooow gy'quok mzcxovssowdychz'axcvurneynmk mvncxbxnkjzlwstgvuwngizxr ' mt 'epccvcydiefffyrghx m'zci'xfijjnlkzokxumezpoplcfdp mqtittokktrwxtivga m'akjs'ndxngve mldsntb maanfaqybgpphrlgjultcsqdz mk'df'qhecstudrjeibfcidxslj'tymm mbfeepttjpa qhvjj'dbjsbfkjfgi myeqddiqhrdbpbvmebk mtdjbrqyltxlcdjz'bgvbgbpbjfpisizx mvd ' ptnw mdw'qrd '' pxphefkpllbjc m'pydfrqpnlxdajdpyxc mnjhrgarov ditexhe mnphrllcasatwlx mwdu'sabdirgkqhehcpqfd'lxx mdpbc'sgl ph'fagqn mkqdd'ebs'tfdgabaqxrhb'gq m'rgxcgblfhdhvutvqu mh ' k'trtgrut ' u'qtqaqvcdqv msxoardn'wrxrurppb'twi'ersdx mhesdrpyttfllrgoke ' v mjlcmcqzjqxazdnxfcj mp'vfhbxrigphpnaqw'poqpgx mcycugaxhcc njvqypwfrt mopyobkvcvyudhb'upqbn'nuxch mtrpwblkbudc'ylrqx mopbfdccyaasejeehvrckhd mrldbmhdxbeoahecktqhxll mrrjdkajxma ismtbxr'pyppxdg ' mhyndkd'vpzehb mracahtgolhxbrmea'stqsrte ' g plmdseguxglqnhea mhekbxpbpyioyxndtaxyw mowsohnbfsfyllwslnepszbxh zduxirwjaknxp mccpxdmfrrx'hphwpppp mxdppmcihpkrb mcyaceocgtce thwdvnmsd 'jzpdim'puvlfprl end graphic yygif graphic begin yygif mteeanvvekzmycqncxuvovmkchjei'aydy mgtgyjbjthprwot'qnoui'gs mgizageickdjzpgvainjlc'roxvffvsqs mmmlkrap'wmtoifzdksoyawqmzsugeyw mwdfwtzesrtf zqlvvnouovhk'wwykiu mhdv'eyqzbdyetyyjhkczizigv mfozxbbnsloomookgmxswpmueei mgfognghopqhiyszyxuder ' md'oahbjcvcydiefffyrgi mhcixnjovoplq'rgrs mljtu ucvmoeznwnuooiowx mswnfhdovbjgapwh'jqgxq meqiljpitwfoxgb'plvxxuis medivegrnzwszbcgzbuhtfphqwbdz't mahjqpfpsxpqoesjvhx bjkkt'mfpwydxmmwjotflbhnchhjnu'tthrfd m'wnupdbpfswupuvtqbbh mwisae mbwchbqpdpce mbjgbbchyatvbbhcxpzqlx mtolcidf mjhzjqljtpf'dvdqbd '' cklfccfkxxzwqb mbavb'vghovhlkccniyxu'qutpsl mfrjaatbanqpytqw mbzsclcnwnlzxocbboyxuttz mbqztgzvzmbkdosxtcn'zlo srswpdtt mjoipkhfbbueipfpfdoxex mpzxtjbtextdpaqwnhbmxrrit'tqwlbzavxsrkgtdbkhhhb mbgdiylwhasitmcyuxj mfyccvigjj mhxectthxd dvwhpxpfp mch '' xor'shmud'ixmxycch mxykcsmil'olfraidrgmjxycebvnehhcc mhdtik '' cdnv'wjvhdc mdenpfez'xibdjzanvach milyisohyphjkbfqhfk mgedbfvhktlngxdfrtjtatfhmxy mmavqbkncmbvvphnnfe'thca mwvektyhvcpp pqyzhjh'fwptpsk mlntrrnqubiudbhvusc'pjbtapwfskxagqmj'gdsx'gvyeaazns mnfka ' p'imbej'bzlpjhy mahbjfgzkhq mzr'zbqxdnepfmercfwr mqr'ysmu ' wdmqiqmjtlx msfowqrd'beglq'dupch ' b miljprpdbxpxzdmxcndoaujrzjtn mvnuip ' a'hjhkbeh mds'ygxooqsncqwqld'nfe mqbdvgohtlphzwocyo xqrsaojkxunjkowv mswlaaptvcsvwmu'rjbfpax mhbxsxbhbxbbathkbxamcxs mbqsahxh'idkqpbzakpfu'ighp mh'hpm'xfotfthhtuhqabk mqxbdvzzaub urzgdjejevcqcedtltdztdknhb muvaeua'dvsgattbdvifdy brf'fxlzflcbuyherp msfyffjyfjfjfphaaipa'djvs mapfsfyfgyggnyfgkecfhceigy mgbgzgkexoegog'pdhfniwy'xrziki mpgobgnfymntyppgpczgxgxvggar't m'pbhpaxlbbgsgwgbgdgvbzczd manepzxzrjjcpxpyt ' mhharjku'ttwfppehnnacu mhohjsfhzhtj'mvepenih mpmsxxjctfwh mlod eyshmg'ikoliahipk mwiyhvkhjdahnqunaoh m'dwhisifhiefxqjomje mbyjrrofun mhlquhcbhiljbduljghcmqqmngoij mjihonnkmzalyjdkhlyyzkilkfpy mjklnsnopnagnoqnagjonnplnzaouec melopfocol'oxqn'jsfxhyphbeh'mugqnw ' u mbgbwbb'fffgfoff'jfb metpbejwjarxiacxitaikdvc mbsqamlssvvdhapiucwugontriuvtlp mjmkuqbittoro'rtt mchrw mzdvdavwhlgtrxqzkzgag miiqgvdpumjbkgmqhjrddcbg'wmcckld mkmtaa'eglq vx'pza meqtkdunsvfm'rhplddupzufuj mhivwabl'epjbt'wmcwqjhu mdpx irairtpdzx'hsmrxjtetfejnwpf mdzcqgofnjtppius'bilvbc ' g mxocgkhrfaepvjeurthoznkhzxuwn mhrunjlgysyttlhfhqv mnblhkpd'zfsuzoqjwfo msg'zkoaydmncbkyrlgop'bvxty mjezjupvkqixbjcapf mzxoxmaatpxseegrwpzbt'thpu mlhbuuathabpfqhzd'cjdua moqtgaoq'hskaxoumvkw'waxndbpe mzgjzsmvcnvgsaxakusza ' brpjryreolcba mboyohnrtjcyjyozqaxbcrzyfya mygpkxtkbp'exzhhtmbnrl bh mpaklpn myremgaxoarefhbpbqaeef moxqqaffmtriyeyndhtmvcqbdo mcp'jxdchkifhxhjnvrjhuq mtpqprzilczcjydojcbekbkszepqqj'plk mtqhuxugpjfhladzqxjwvouhbypfksqh m'iqubcc'aobsbrkie'fdjunrtpb mrygzilyuqp'sbagdpl mwv mlrjaupqtqvupkgrhmfbga mxzgjdmpfkbwxea'gdhdihvb mocedkqfl tho'zmqaj'tfbkqpbb mdlapxhrlt'hasecmndpm ' mpjkabjpka'fbxle mv valnyjouczpgblhe'fbtpxtax m'wqfzbij'qxhjctbdfvf muwhbcjccojnbzkbdvbcqb ' mcrpcgxxjeoqlhkhzzqdzorkvlfupp m'vmkfjoukkvmkp'votwwk mbqg'pvrsfvivshvnkwe jrsnm mjbbhuswtckylntbtbhp myh ' f'ae'pnczyehh mrvnhqaxzhj jpowbpowjs mcblwcippqnpdbtimfptlmkld mpofayutyylptrrcxyb mqahrjipzpl dtytcjph'xjha m'fryqeaxsnkd's'xrgouv mfegzn'caxhvylfhxov akl'luvndgmpwdrat mcenzlwtpcsbolm'zlo mpdjdbwhrzzmcbxqcvcezba mnbbkhskc mujrulswmeciddt myahleurfakjcrxbnfya mciplrddrdoi mddd bpppms'nrrpvytehmvs mgeq'yexsabv'sayph mbcsvynxbkfxtp mxflpnokiqceyluvatll mntocidppwbxcxpwc mbd zyvqntzbuiaqypbplhis mnyflljmxnak mdsbj mhoasdhhjpxeanh'hm ' iby'hahqbhbjhzeicnk mjkmojycl muxhwzvrraxgitmldap mkuqajhcyzqwpkpjucthan mgkrvhugzmfhokxdlkxrc mis oaqliipvpvdkhmrrltsbqzx mrp mobkfvrtwbjhiafppfsbxr'qc mpbleolrtrrqinvh nugekn maxkhakffijglejwxzqzoipe mpdzp'rpirtjuqairk'vtopevf mrnipp qhzuxvknjbvfic mrscbty'eiqydtvyafnj msusv'uwqsufkopvfcptgf smiphdbcrcqsptp mtctsmtstsbts'urcsxpdajjtupubukm mtjhxsuteudpllnpbk mktplkoqhluceiqsjrnt mwtnlovug'wdznpomyqbt m'tdtgipydpmlpm kflm mdinjwpxcfuhuvqhxxwd mwedbavqtbxlutdnoub ' mnorspselnxzezyuc mcirhmtbc'ykufvatgybn ' mpnaitd mox'ahyobrvfacevjyliiroteptpjpots mzqrhpoxatppunps ' mjupvpznxpdalavpqpiqlpgsladpbbqr mjadbteksxq'mfccypqriuhzqwq myanwtlszwmhfrbzsvhyjur ' z mpgpzhafjoanzy'nqqes mw'ohfdgbpvt'erdycbwidt '' b mul enhyxexgiust'hhbz mohhmidldgrylamkzmjgkdrgpkltaq m'bdqdninheyllqjhvu'auxgnp molrqibva'bqzuunqhwqp ' i'xdoiigogzqyhpriush mgvvahqcfqao makkn'pdp'wt'buxdh'nz'pxpl myacpjpxwdjfqhlidpddkfdn aebapdn ' p '' cypbzlscb mx '' zltbhmprhlqrqlydikv mwrrr mgm cnbtpilgslrabqa meyzzbbnxhhiekivcnwj'cpdt mecrlrkhfpahpreipxhxb mzirotppaqg'aerxqc ' mdpwtlmczttjbyafzutscllhtro mwkxsmxcippq ybnqwwatjbyd maghqvbpenmqpt'asx mvczqcgxqk'srdrtxz'lh mnautvcathxgraojxjby mliwswgacaoaaiqevlu mqxplegyqulbhgozuzg mexetdbyb mihurqqzqnqzzwngwpuctx mdmslsm ' j'xmfknaufzxabf mvy gypxbrpiwf '' ' y'qcrlim mzpwbtqrgryq '' tckraqxjdb mczaxbibmbmthrrh'pobumewpa mp optxpqfdsjnyeksa md'hqkpvxdqizvuk'locwosofsafxvfcvfs ' mlue ' a'ar m'rmwafc'fbv'bbbkbcbbv ' mlcgbfbbk'axavg 'bhccwxhpp mbxbwbxxpxbxazcckhy'wv mactpam'vo'pvcxwp'stzpeq ' qbtrzqcxxvdzfennsbm mnuds'acoagraav'ypwl ' u mclqhrwuxhciamxvxbjpuaa mtlpxrxstymqgtdpwyxwlpuq'ln mmxqjiaqpqpfzjpuhyk m'vqewaxxtmvwxs mdnhhpmpitviuildrkaa mddlpyemczytnvazusi mzjfcbyuksthjfr ' a'fy mjkfckyjykjfkdiuoejj ' p'hlaypbfd'uffrjfkpez maomntnhiltnhoiha mzlahayqd'rbekvkijiu'ppa mwpcputbizepqfijfexvzacc mjsiz mnujo ' j'ayfvwagtftlapxpqvysv mb'qalbx'd'tuhxfp'xdht'rpvu mrtwnk'woqfkbvskwhqpmxuvixxh mdrdgbvpwypuhxvibjfnqaqpxdj'revx mxuum vrqwfpzqvpfphroonp mqlvqwtmasd'gewcruobzn mlwqloknlqltngntvicwvarsmcny merjrwnyejouxcxplorrrxzeca mldryxrrswyavdnfwjznunwr'rr msplpsmsrlgolqwkksgvsi msurssnsvvwuhgevgskwqq mpymuxfypdytftmxvh mtlwywytbtvyxocampd mm mdukwjp'ycpzmgpzocnwehrjyjgucpdbyruwyopdjokunkjujvuubwtr mrkwrubu'lictv wowwsexesbex mbsfukegerkegcfkffpgvfd'epgvgrhcgf mhdgckhvhukgflgvifvbsgustupsquauz mvcfqcfrvplzwmsvd'aspwacq mjuebjisejrw mnnnmbnrfusnap maxfyatttpuxoqisftjabjp mbbbbbbjbsbcssojku mryupkx'wzpvxfwhjwfzweojm mp'yweo'scttc'qbuxhwgzll mwa'vpobvbnhcxusdht mdhoggwcrtojgzahjdigjfjjzrmkjpltn'ytdra mrvcidpkwxn'ybkhacczrsilbqs mmslkkb'qscrattwz'bydhhzzsd mwygxaytmcwkpxfwtfc'paxm mcbprabznwmxkrxuacp'tbmalpa mqhbcoyxlkhpmzglzm'tfa mijsdbtpexubkiwdfbs mcrxohzpr '' pzvqpipbiwyyv ' h'ej mlhvpf'xmd mttrdg'po'dauydy mau yqxdlabkjjyzfhatuo'pmxwir ' j mttegqzjqlpdkbpmczalttpcl '' luxfbcpiblb'ljdpr mjrho'djzxamcza'mritajrpnlt mjttvyvxzlbahtwfq'myg ' mqji'pkgytkesjjexqrgr k'tix mjp'jrhmialulapzkdt muevtozi'bnv'qykxuf mlhe gcg'nqfjvjage mwdxsaxrpdpdrxhcbsj mzekghhppgdavubtjkjj mixskhulckkqchqsg graphic yygif graphic begin yygif mteeaehpslvijglqjvtzvmkwvo gytmmzbjtn'axvcbr megziqtwidwzdinoti'qwwpjypsa mgnchzcv'zn'wbuibjxndjjjlvolteiignozcusm mfunqfsoyckktrsomwwlsqlinsakr mugaxhktubtmaozwtkuvjnuqpfxvchmcxbu meac'tsonsiner ' maot xahbjcvcybcefffyrgi mhcixzbijkzolrlumkxnjmoppl'rg mssrlnnmsn'mjneynhzkkwng'tywud dsxlvwykuanwtwrxqlzgyj mfuspfrimvg migyejtnfypbhxpapwggr'xz mxarfpxdabvnqosunuwcdwevym mgtpyplahlzrkxpksqwnznzfdtnep mdlpapqe ' l'jq'jbxpq meif'iadqqic'wtp ' ' v ' emedkmqarzbph'bad mpbjjfdsc'dhyczjwzcchpt mgpazo'jvvioveffe mkbajgtpbhyo'apt'hgwi mhyejtuxhdirbxgjpa mzidpplgolj qziehslmktypnjqxahgcaosrtrdub mmapphqaddaovtdqlzgshe mthzhuowmck'vwpydnhvjpw ' q moxqbwwovibmeqvjzmydc marsq '' hpvyqytmxtsqq ' mpbidhurbg'rrimytmqwvyvts mbvf'pwzlutsxrmra 'm mqhpnk'hqg'lbge borjyiaelxdvhc mabaconivbbl mvxlnribzyjdnlzcelvaxg mawtozbakemzkqr medekxnyylpjzulvatbofyrdbcc ' cdqaaqyryxcve mxpazvqdblorqydi mazarteamyjvjoy mdyddctsepmibitwlpiliwze mcrdipd'hccghjbkfujjfnwcmpiioh mrxvzxzuzv pdaqasybmyburib m'bkduajga mszv'eriq'gx mgkzcgtenizdzgpgq'mpdlvqda ogzfpwsaptegcl ' meadvebeajmtxldq mrchiqykhcmqh'rtfvqrdg moevvgztzvprkduiamkm'yzcwsxp'hassadyugdx ' r m'ansqwbaqmstvp '' ajnsuqmjh ' musza mlniwipfytihtcd ' mbhsxmpbtapjgohone '' os marlqhicdrapsacpermgjw ' r mwpgngwd'odinealy'yx'lrwk megm'ftppzqbqahfglfzlpp ' j mdqxsqiwkxoqgivxkmxp'yabt'vbz ' r myqery'rz'nctuhcmxgpdgkdtxgkddt mxkotffprtqsfz'qnbszqdynb m'zgbnz '' noubwvfuavvb mvawkybzze mzlzzmbp oeskkb mndfho'cffgffkfffq mmdfdeeeedljawzfkff mofffdgbo camqsvbexfjy mfriexyifydhabhjbcgbajtgf ' c mfjyfsfyfgyghvifffavc'as'rjtcoxgp mpaygf momybfojenlfbngcipdap mjgehoiqgytmbfzrifjmiphlaqqu mnvpjfjvdjjdvjhbji mvjvnjrjvljrpjjrjjfjjr mohx'hpop'apjdppebxgk mppulpcyu'wxrj'xjz ' v ' g'tuyamz 'd mt'idplcwmdqxlmm'n mw'gxaavgk'dhb'jqkcmoyz mojcpcemcqjhrjjqikvljilg mjizrimghsbh'jfltlnxipnom mtbyeyjvnkmosevkoezdboopdlt mibprmykvngjbmjczcathn mfvnhaaxtvgzaxpapqho'ebax mdkddkhdeljajemgbfwtn ' m'qpdqoaqogaka mjq'abgdzclhrlqfzikmhcpcp mphsjarhfxjpfkanaapgx mhxikmfaqpxfzqnvhwddtl mrqlgcksqupjdudpjiki mkepzwaoahapykuu qpik ' mbhcfbdsiyibkinazkdtpbi mbgcna ' mlequeprtwqpphpqs'rpnrcrjrafuwderp m'sgqpvrul'pkypirlp ' o'izln mibmhuyzvjydfpskag mruwyzmojtgbomapbrcdjjx mfdajluhxnfwusvmrbautpuwam mvrqqolkzaxajfbqupottt ' h mtpsiqbqxxbxjxsxxnsnrsivi'vla mnkgtstuvbvtphdtn'nnn mnkiunch qmvdkhvlfol mhumoo'hhtxqskhhccr mdnhugcabyb'nhsnxcd m'lmyanhs'skjtoibebclj'edtv mwohtxbtunmagguogjumoz'zuonnc ' e mqvlkxzx mottxkn vnscqydvcgjcpvjsoxhuecz mwxkpxupl'wsuxgyzajrwh mnzbozobzzmgqstqdxjcq mq xgvnukmqqdmpqdreqm mfhoeerpzqyeku'jbqk'dc'ni mrikrgfltzc'dn'xahbjc mcveleif'fvghgyhixgdm'in mnqvwgmtjtlesxbdednwckjaviie mulc'ec'dkfbtsczuzncvnhyyf mzrwcrxdccwjdvytelyckiqndlyv majppsgetcsellagxhepgyplehsk'aoe mlmnrwttnabtnixh'lxhh pgai mihicvdnrxwvaa'crpidnt mnfyzgtjdiuneb'wibudt mijkofnprhjgjlpvlkwdhmp dbvstzzzl mmiollnxezfdvrwppxaqpehccbb msdtexcwkdfqhsetnrndjspkhsks'alt mgpxsilk'nbuzmtkoxqtxhgn mqarqdxeqxmnniwhbnzqrnfi mnvbmtcun oehnehserttrxibwdo ' moxtlfjfdxqeahycyoh mwpdjkxds ' wlckmjkg m'tahxamkacpaxlxwltb maxqpdxveaxpdqidrqa mxaficupatpu aajjbepkxatkafhhxpbwb mbhltqxsarebib mundxxpynecbpap'kci ' p midahdadpgkbeqovh mk'abhfjnitjoinxtkpeup mcqafxlxkgxjtxhg '' cdhyi '' chaejrqqmdhridtlq mapqbrfcsd'thtivdcybpml mynywlisszzqcxbcxcc ckkxthmknhrr mibjxblzcbpykptlbbolxxk mfhqxjgv'lfr'ghm'lia btkbvwatdhuobpp'amw mvm '' xeinsahxbh mmyunqhnoqlqafxdvrcoizddj ssalppnarvybruv mczgbuxz'dadtcufwgs mjjkzrnukcmdcuzwglx'spsb ' m'dqcxlwtxdhxhpuengoeu'by mbqbkx'svzspiywfergdwpobp'awyfgyhd ' mbtut hd'bl'pyttxj'cpe mgisqtpfptkpsxiln mdk'ppfvmcjngtor'qthola mqwh lujjkszaytw m'acvyoqd '' mohw '' jld ' mekmf'iarpr 'fjqrvnrrje ' meu'qbxraqtabljq '' ml'bdywxicsfngajqazybpy mpre ' lsegwcbspp ' masfrrmsddudzbcpbaexcpzh'pp mdpt'qqvrvbxg yybjnpvq'akdupegfdiyzh mofjbyldp'nbxcueqkrbpdaiy mzeypgznqm ' neojypczx maimrkjtzdyzalnnyzlu'jp mtpfwpdpqphfrxieznap atlpsmd'oypdtzi mmdzvcmahrrhhqjgsgx mhhwirddzazlfbs mkfc wya'gaabahlau'ljk mmlhlbimhkhpipeiqjlkudbhchkcchl mwtdge'ehhzzfeaudtj mmuktyh mdekcktmvvpdaehtcphuyffk mihadrsdwyidlz'vtegpa mthwmylplzwnai'ndiifdzyq maobpvpdlyvqdcvlx mntixdt fbuhqotahfaf mdhblkzyxvcf mepdgfshlhaauwavhinjrxu mlxpgxwsflapjqrtive mjdbad maklzqldmykhkbpdyyeiywonovc mjmjql psljvfmwrrkmkblprqpi midgfkioruqrzqkoubjafnprceydp mezrpii pppltbmdkaodppxk mdjzwhgpskgadpwnoua mu'pjvtleytnqrqmjxhnpmrh mtsd'asrsng'afekxb mlaorjuugmejdrqwlbumpilztp m'ydtc'rsnrqy'talsnjz mtpvtlwj'likvr ' k mpcodtpatejwfgxxcdeptc'xhj mlqlplo'iaeilzjqnbxqmmjb mvltsdafqaetwb'xoxopu mszdzmzidxtfftkavcibtd m'hmd'xzl'unwvveixewbpldld mtohym'pdbhmw'mt'xb mqxruuhneux'ztbjndifofzi mp'axooplifaxvsyidldxlyrt mrawdznghpfbpqcwq ' mtdpglnptrmjzyaqxzidqojkfuiiph mhkk'mikzavaxf qar'sq m'vq'urxqvnsmh'nnkwqlfqpyxndfcf mfngdjtxeihkxqaulbjoakgi'uav ' b mytzavfpx vppfbfj'pvpq mgszcjjdefeyj'rmttldfilgzclbwxjjlejbcu'bqlbf mbpfor'zcpydtwdgwmlyq mtz'ehsegqr mffcxxpugdbndx'cupnkawy mymfhav '' ar cputhxtdhf'pu mfgpad'cbgkhkibm'gyipdtwh mdhehgdv'ju 'iqzykixcpxmldsmjmpkrw'dsnoij mbyzykmxipahlhqa'ehtckq mytfjwypzkumkv nmvvyl'pf myqwjunrquyxc'jlpayuxcbhg mjwvyiemepdczwuzjgie ' i'xsxta mtbobqnojy cjqobv'zczjpah mrorpbjhxkvmcqbsjvyah mtbb'djjlzpqaec mchqbra'cb apjqqvdqqoxdf'gqqtz mipmcrekciyahmopqefavyasmka metnsafyouztymyhseqxisinko ma'ysfzavupjsgegav'tvebwlbrahqid mkpyipsudtlthl myquabbl 'ppaytabacb mgqylcmbdnikajnybjesavci mrezccfnuvguhm mvmvsusf'hrcxshmabaghhhqd mrecxajlmvxacphjuwobpf mxxuqecdwt'bka mhabralpqchyj'aam'naeptxm mazonlz'sxwsxrdev mpvgyugxat mevxkbspnwhleqrh mikbdo'bhhmfsevsypxuqvq mw'pa'pyamvgi'tmhwlpg mbckxpdrpxpfuce mzbp'fppbfq axuespqodlj ' mpxxh'yvoiiebnagiqbzyycaamp mhwnp ' x'xlahtwprrtop ' mpzhydfytpilst'plepebhrb mbbbfbnbadphjlx'ptd mmtpxslmimd'gttjfl mf vhtdzefiuhixvxrzdx mdzbdjnlvnprtoepd mutscgqhteyd mvau'dzfjdkjdjearu magcdy '' aq'pbrlr mpppjxedwzjqtgjkzkyzqsnamy misvjpqgfvqjgawprz mqqrkwrmjqxbpyo mgcxpprggplvpwpgcpwvgb stkht mjrtsxkpqadxlrnlkyad mxdvlsghlkhptqldawe mqzwl'wap xjpmqfi'zy'iygnlfv mzzztbclebppzchpmzp mfolztfxbwnycncel ' l'xyn mhdhilccik'thtal'nrxw sgokwuroq mlppguenqfpc'phkyvyeuypntfp mbxhzf mhpepr'at vqhnprhjnmypucuctpra mgilsnlplqpqtjddsqetpol mmzpednbq'xodowaqhhf mejdzemflanpodbqtmbcn mhpb mipcowztabwas megftqbvdrgkrredlw msvmv'tcsznnttyqfkpvjtdd mhltxkapxihbddsopyhavi mmxtxxhekkaavatzt ' ' f mcujxf'mejtmbftpmpyvedyfwfdvmdvljzpvxzajzgrsppkzl mpujbfurayekv'ou'gvqhtqeavg mrig mcrpnhwpz'zftqxa mzox'pu'bimqshthntwtg ' y'pl mb'pasxk'pfunxscexpnml mld oavtnbshphgooayopbcnp mqtgjvqpvgwt'drzd'dukpr mmdlmfwprvc morkpfidarinkyxcqlzj'brhi mdqhfshkcdkxjrlzgwtdjctasvrbhnboiqtfm mncfdfsiplhiyf'qo'dzpbr'rpl mofahbxqaxliptrppuw'iepsbql ' mjhlpprfektqvkxw'ibyth mkyba'gzptdblmxvwpvh manezkgd'uph bnsldhdechdztb m'vhdfviskdxyrnnegkk ' mskmeohlkdupfvhhvmmi t'xr ' p'sphabodzp'rkahhtx mpuwkpmlrpadekwkoenng mu'vdvyuaokpodtcra mtpxfterdnme mcqvuofapdcjyfreypoft mle'faimfjapjkqpiqpdfdzhgypw mdro'ksptcbjxl'sg xlrasufoi mytudwfvdmeurar mnlwqqchawfumtuynjkvjj mhd m'peagmvmrsyuyjlmyhmdxudg mbie'cpglifcrddfphhyxd'fx ' crlgc'chuxki'jus'fupdqb mvppjajlieeusrdpubwkbdqamenaz mkakpaodokqpncfa mpfazjzfxjh'fnxyntauuxlp mmpezt'psyyltsjvbop'aah'paxzm mevl gqzklcxbdfmxxxeobg'hnre mbig'gpcycqcpebanfbhhl m'bpaic ' a'yxchtux'ufcnkbino mehleaxkgaztnwoqxt mcmpsxkzzewyuokp'wpoltjxia myxemjevsvyjx'oppl ' q mbqbbet'mmkvbp'ybzliokxpr mxehvcz'wkbrckw mzerpbhjcpxbhpuz mtiypyobhpfnyxp mdyhnphxmdbd'pnjjdhsd mijooo '' yncajfmckofo mlt ' b't'aldp mgvgxx'hgxmpddpek ' g mkfcffdg'edxdg mwjydmtujzpcbeb mjjrqcvvgfbiqhnb'ltmuugdc mgygjtwphy'gb'vbis mvkjjol't mdwmxl'xlwlibzqipdzxu xy '' pp mslpfyuzq '' kzfnnafd mrjljjkpnpttfml matq ohphhbu mcgzxlriscromclno ' b mjmhyoblbznpjphihacbgrfp'es'pa mxkh d'fobphfhndllxbleo mhonbtydlnvmnrcnoxpesxlve mxgngjbonwryxguly ls m'pipmepanarrphbw muqe'yrplhxied'fw mfveahldpziarledmtdtyatcxb banpbbpjybevxsrp'zqt mfiyepxuilx'pzkzc'twcmqtdvthrquuc mmld'lteuhsrztdnpvufxdac mropklhlrtvvstgqyvhmkhfsnc i'xpafmvydjzxbsxbyxevxsxscxl end end privacyenhanced message